{"id":76303,"date":"2021-07-29T08:15:55","date_gmt":"2021-07-29T12:15:55","guid":{"rendered":"http:\/\/stateofthenation.co\/?p=76303"},"modified":"2021-07-29T08:50:11","modified_gmt":"2021-07-29T12:50:11","slug":"the-whole-truth-covid-19-pandemic-covid-vaccines","status":"publish","type":"post","link":"http:\/\/stateofthenation.co\/?p=76303","title":{"rendered":"THE WHOLE TRUTH: COVID-19 Pandemic & Covid Vaccines"},"content":{"rendered":"

<\/p>\n\n\n\n
The Whole Truth\u00a0<\/b><\/p>\n

Covid-19\u00a0\u00a0<\/b><\/p>\n

Covid-19 Vaccines\u00a0<\/b><\/p>\n

Professor Jean-Bernard Fourtillan\u00a0<\/span><\/p>\n

Doctor Christian Tal Schaller\u00a0<\/span><\/p>\n

Doctor Serge Rader\u00a0\u00a0<\/span><\/p>\n

Fr\u00e9d\u00e9ric Chaumont\u00a0<\/span><\/p>\n

August 20, 2020\u00a0<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

The calamities of the Vaccine\u00a0 they want to inject in your body<\/b><\/p>\n

4 fragments of HIV1 <\/b>which give to\u00a0\u00a0<\/span><\/p>\n

vaccinated people: <\/span>AIDS syndrom <\/b>and\u00a0\u00a0<\/span><\/p>\n

Immunodeficiency <\/b>as a consequence\u00a0<\/span><\/p>\n

DNA sequences <\/b>from the <\/b>malaria germ <\/b>which\u00a0\u00a0<\/span><\/p>\n

give <\/span>Malaria <\/b>to vaccinated people\u00a0<\/span><\/p>\n

157 additional DNA <\/b>and <\/b>protein sequences\u00a0<\/b><\/p>\n

(see <\/span>Patent US 8,243,718 B2<\/span>), whose <\/span>presence\u00a0\u00a0<\/b><\/p>\n

and <\/span>role <\/b>are <\/span>unexplained\u00a0<\/b><\/p>\n

Nanoparticles <\/b>which will allow <\/span>definitive\u00a0\u00a0<\/b><\/p>\n

control of people vaccinated <\/b>thanks to <\/span>5G\u00a0<\/b><\/p>\n

The ChAdOx1 n-CoV-19 vaccine\u00a0 they want to inject in your body contains\u00a0<\/b><\/p>\n

ChAdOx1 n-CoV-19<\/b>: <\/span>C ovid-19 <\/b>coronavirus carried \u00a0 by th e vecto r v irus <\/span>ChAdOx1\u00a0<\/b><\/p>\n

Nanoparticles <\/b>described in <\/span>Microsoft Patent\u00a0 PCT\/ U S201 9\/ 038084 <\/span>,wh ich\u00a0<\/span><\/p>\n

\u00a0will c ontrol you t hanks t o 5 G\u00a0<\/span><\/p>\n

Disinfectant : <\/b>s: <\/b>either <\/span>T himerosal\u00a0<\/b><\/p>\n

or <\/span>Formaldehyde\u00a0<\/b><\/p>\n

and antibiotics<\/span><\/p>\n

COVID-19 is an artificial coronavirus made in France by the Institut Pasteur from natural Sars-CoV coronavirus\u00a0<\/b><\/p>\n

Covid-19 <\/b>is the <\/span>result of several genetic manipulations <\/b>of a strain of Coronavirus <\/span>Sars-CoV,\u00a0 <\/b>associated with severe acute respiratory syndrome (SARS), <\/span>resulting from a sample\u00a0 <\/b>listed under the number 031589, <\/span>collected from bronchoalveolar washings of Sars\u00a0 infected patients by scientists of Institut Pasteur<\/b>, <\/span>before 2003<\/b>, at the <\/span>French\u00a0 hospital in Hanoi <\/b>(Vietnam)\u00a0<\/span><\/p>\n

– 1st Step: Sars-CoV-1 <\/b>was pr oduced b ya <\/span>first patent <\/b>(<\/span>2003<\/span>: European Patent <\/span>E P1 69 48 29 B1 <\/span>and \u00a0 US Patent <\/span>US 012.8224 A1<\/span>) <\/span>from Sars-CoV <\/b>collected in Hanoi <\/span>before 2 003<\/span> – 2nd Step: Sars-CoV-2 <\/b>was <\/span>a continuation of the first US patent <\/b>US 012.8224 A1<\/span>, p rotected \u00a0 by the <\/span>second US Patent <\/b>US 8,243,718 B2 <\/span>(<\/span>2011<\/span>), <\/span>from Sars-CoV-1 <\/b>– 3rd Step: Covid-19 <\/b>was produced <\/span>from Sars-Cov-2 <\/b>by <\/span>inserting <\/b>into its genome <\/span>4 sequences\u00a0 of HIV1 <\/b>(RNA <\/span>AIDS virus<\/b>)\u00a0<\/span><\/p>\n

\u00a0<\/span>Finally\u00a0\u00a0<\/b><\/p>\n

Covid-19 <\/b>was <\/span>made in France <\/b>by French scientists at the Institut Pasteur <\/span>from <\/b>natural\u00a0 <\/span>Sars-CoV, <\/b>then <\/span>transferred to Wuhan <\/b>where <\/span>the People of Institut Pasteur released it,\u00a0 <\/b>\u00a0<\/b>unbeknownst <\/b>to scientists in the Wuhan laboratory and the Chinese government<\/b><\/p>\n

When she says: “Covid-19 is not a Chinese virus”, CHINA DOES NOT LIE!\u00a0<\/b><\/p>\n

Doctor Fr\u00e9d\u00e9ric Tangy is the father of the Covid-19\u00a0 <\/b><\/p>\n

Doctor Fr\u00e9d\u00e9ric Tangy\u00a0\u00a0<\/b><\/p>\n

Director of Vaccine Innovation at the Institut Pasteur\u00a0<\/span><\/p>\n

Publications related to coronaviruses and vaccines<\/span>\u00a0<\/span><\/p>\n

1- 2003: <\/b>Inventor in Patents <\/span>EP 1 694 829 B1 <\/span>and <\/span>US 012.8224 A1\u00a0<\/span><\/p>\n

2- 2005: <\/b>Publication: Fr\u00e9d\u00e9ric TANGY and Hussein Y. Naim.Live Attenuated Measles Vaccine as a Potential\u00a0 Multivalent Pediatric Vaccination Vector.\u00a0\u00a0<\/span>
\n<\/span><\/p>\n

VIRAL IMMUNOLOGY, Volume 18, Number 2, 2005, page 317-326 <\/span>3- 2011<\/b>: Inventor in Patent <\/span>US 8,343,718 B2\u00a0<\/span><\/p>\n

See <\/span>Document 2<\/span>
\n<\/span><\/p>\n

4- 2014<\/b>: Publication: Nicolas Escriou, ,Beno\u00eet Callendret, Val\u00e9rie Lorin, Chantal Combredet, Philippe\u00a0 Marianneau, Mich\u00e8le F\u00e9vrier, Fr\u00e9d\u00e9ric Tangy. Protection contre le coronavirus du SRAS conf\u00e9r\u00e9e\u00a0 par le vaccin vivant contre la rougeole exprimant la glycoprot\u00e9ine de pointe.\u00a0\u00a0<\/span><\/p>\n

\u00a0Virology, Volumes 452\u2013453, March 2014, page 32-41\u00a0<\/span><\/p>\n

5- 2020: Paris-Match article from April 9-15, 2020\u00a0<\/span><\/p>\n

6- 2020: Paris-Match article from May 14-20, 2020\u00a0<\/span>
\n<\/span><\/p>\n

From Sars-CoV to Covid-19\u00a0<\/b><\/p>\n

Sars-CoV <\/b><\/p>\n

Collected, before 2003, at French hospital of Hanoi, by Institut Pasteur (sample n\u00b0 031589)\u00a0<\/b><\/p>\n

1st Patent in 2003 <\/b>Patent EP 1 694 829 B1 Patent US 012.8224 A1\u00a0\u00a0<\/b><\/p>\n

1 DNA sequence of 29746 nucleotides + 157 DNA and PRT sequences inserted into RNA genome of Sars-CoV<\/b>
\n<\/b><\/p>\n

Sars-CoV1\u00a0 <\/b>Fr\u00e9d\u00e9ric Tangy\u00a0<\/b>
\n<\/b><\/p>\n

2nd Patent in 2011\u00a0 <\/b>Patent US 8,243,718 B2\u00a0<\/b><\/p>\n

CONTINUATION OF Patent EP 1 694 829 B1\u00a0 Patent US 012.8224 A1\u00a0<\/b>
\n<\/b><\/p>\n

Sars-CoV2 <\/b>Fr\u00e9d\u00e9ric Tangy\u00a0<\/b>
\n<\/b><\/p>\n

3rd Patent in 2019\u00a0<\/b><\/p>\n

Patent filed in 2019\u00a0\u00a0<\/b><\/p>\n

International Publication date in 2021\u00a0<\/b><\/p>\n

Insertion of 4 fragments of HIV1, corresponding to short segments\u00a0 of amino acids found in\u00a0\u00a0<\/b><\/p>\n

the gp 120 and the Gag of HIV1, in the Sars-CoV2 genome\u00a0\u00a0<\/b><\/p>\n

Covid-19\u00a0<\/b><\/p>\n

Fr\u00e9d\u00e9ric Tangy\u00a0<\/b>
\n<\/b><\/p>\n

Covid-19: an artificial virus made in France\u00a0<\/b>
\n<\/b><\/p>\n

First Patent US 2007\/0128224 A1<\/b><\/p>\n

Patent US 2007\/0128224 A1\u00a0<\/b><\/p>\n

Claims 1<\/b><\/p>\n

Patent US 8,243,718 B2 <\/b>continuation of <\/b>First Patent US 2007\/012.8224 A1 <\/b><\/p>\n

From Covid-19 to ChAdOx1 n-CoV-19 Vaccine <\/b>Covid-19\u00a0\u00a0<\/b><\/p>\n

Insertion of Covid-19 genome into\u00a0 the genome of a viral vector\u00a0\u00a0<\/b><\/p>\n

(<\/span>ChAdOx1 C himpanzee DNA a denovirus)\u00a0\u00a0<\/span><\/p>\n

Jenner\u00a0<\/b><\/p>\n

Institute\u00a0<\/b><\/p>\n

Adrian Hill\u00a0<\/b>
\n<\/b><\/p>\n

Director of Jenner Institute<\/span><\/p>\n

Covid-19 vaccine\u00a0<\/b><\/p>\n

ChAdOx1 nCoV-19 <\/b>(<\/b>AstraZeneca, Sanofi<\/b>)\u00a0<\/b><\/p>\n

Insertion of tracing nanoparticles\u00a0\u00a0<\/b>
\n<\/b><\/p>\n

in the vaccine vial to be injected\u00a0 into the human body\u00a0\u00a0<\/b><\/p>\n

together with the vaccine\u00a0\u00a0<\/b><\/p>\n

US Patent WO 2020\/060606 A1\u00a0 PCT\/US20 19\/038084 Microsoft\u00a0<\/b>
\n<\/b><\/p>\n

Final vaccine\u00a0\u00a0<\/b><\/p>\n

Bill G ates\u00a0<\/span><\/p>\n

Nanoparticles <\/b>they want to inject in your body\u00a0 together with ChAdOx1 nCovid-19 Vaccine\u00a0<\/b><\/p>\n

Satellites for 5G\u00a0<\/b><\/p>\n

Task server\u00a0<\/b><\/p>\n

Nanoparticles <\/b>5G relays<\/b>\u00a0<\/b><\/p>\n

injected\u00a0\u00a0<\/b><\/p>\n

together with vaccine\u00a0<\/b><\/p>\n

Vaccinated people\u00a0<\/b><\/p>\n

Nanoparticles\u00a0<\/b><\/p>\n

Mobile phones\u00a0<\/b><\/p>\n

Bill Gates\u00a0<\/span><\/p>\n

Thrombinoscope of the promoters of the ChAdOx1 nCoV-19 vaccine\u00a0<\/b><\/p>\n

Bill Gates and his allies\u00a0<\/b><\/p>\n

Bill Gates <\/span>Emmanuel Macron Jacques Attali Agn\u00e8s Buzyn Yves L\u00e9vy Olivier V\u00e9ran\u00a0<\/span><\/p>\n

J\u00e9r\u00f4me Salomon Dominique Martin Tedros Adhanom\u00a0<\/span><\/p>\n

Anthony Fauci <\/span>Fr\u00e9d\u00e9ric Tangy <\/span>Adrian Hill<\/span><\/p>\n

Ghebreyesus\u00a0<\/span><\/p>\n

WARNING\u00a0<\/b><\/p>\n

– <\/span>Covid-19 helped spark a false pandemic, a<\/b>nd <\/span>spread fear across the world<\/b>, <\/span>to make us accept the Covid-19 vaccine.\u00a0<\/b><\/p>\n

– <\/span>By seeking to vaccinate the entire world population, the sponsors of this vaccine, <\/span>Bill Gates and his allies<\/b>, want <\/span>to enslave <\/b>and <\/span>control us<\/b>, pursuing two objectives:\u00a0<\/span><\/p>\n

– <\/span>Control the entire world population <\/b>after having vaccinated it, <\/span>thanks to the deployment of 5G<\/b>; <\/span>– <\/span>Limit the world’s population<\/b>.\u00a0<\/span><\/p>\n

This vaccine is very dangerous <\/b>because <\/span>it <\/span>will cause<\/b>, i n <\/span>vaccinated people<\/b>,\u00a0 <\/span>deleterious immunodeficiency<\/b>, due, i n particular, t o the <\/span>presence, <\/b>in its genome<\/b>, of <\/span>4 RNA fragments from HIV<\/b>, th e <\/span>AIDS virus<\/b>,\u00a0 and, moreover, <\/span>DNA fragments from <\/b>the <\/span>malaria germ<\/b>.\u00a0\u00a0<\/span><\/p>\n

MEN WORLDWIDE MUST REFUSE COVID-19 VACCINE\u00a0 THAT BILL GATES AND ITS ALLIES WANT TO IMPOSE ON US\u00a0<\/b><\/p>\n

We invite all people\u00a0\u00a0<\/b><\/p>\n

who consider information\u00a0\u00a0<\/b><\/p>\n

of this video as Fake-News\u00a0\u00a0<\/b><\/p>\n

to check their accuracy\u00a0\u00a0<\/b><\/p>\n

on the links provided under this video\u00a0<\/b>
\n<\/b><\/p>\n

Data Sources of Information for the Truth\u00a0 about Covid-19 and ChAdOx1 nCoV-19 Vaccine are presented in the attached PDF below<\/b><\/p>\n

PRELUDE\u00a0\u00a0<\/b><\/p>\n

To fully <\/span>control <\/b>and <\/span>enslave <\/b>the <\/span>world’s population<\/b>, by monitoring and weakening it, the leaders of the New World Order\u00a0 had <\/span>nothing better <\/b>at their disposal <\/span>than a Vaccine<\/b>. With this diabolical intention, they had many genetic manipulations\u00a0 carried out, on the genome of the Sars-CoV coronavirus responsible for the SARS epidemic that occurred between 2002 and\u00a0 2003 in Asia.\u00a0\u00a0<\/span><\/p>\n

The <\/span>Covid-19 <\/b>coronavirus, <\/span>different from Sars-CoV2<\/b>, is an <\/span>artificial virus <\/b>that is the result of <\/span>many genetic manipulations <\/b>carried out on the <\/span>natural Sars-CoV <\/b>coronavirus, which successively led to 3 artificial coronaviruses <\/span>Sars-CoV1<\/b>, <\/span>Sars CoV2<\/b>, and <\/span>Covid-19<\/b>, described in 3 patents filed by the Institut Pasteur, which provide their intellectual protections\u00a0<\/span><\/p>\n

In its genome, <\/span>Covid-19 carries<\/b>, among other calamities, <\/span>4 RNA fragments from HIV<\/b>, the AIDS virus, which corresponds to\u00a0 short segments of amino acids found in gp120 and Gag of HIV-1, which will place all vaccinated people in\u00a0 immunodeficiency, and <\/span>DNA fragments from the malaria germ<\/b>.\u00a0\u00a0<\/span><\/p>\n

Men around the world must open their eyes and understand that <\/span>the natural Sars-CoV <\/b>coronavirus <\/span>poses no danger\u00a0 to humanity<\/b>, <\/span>unlike artificial Covid-19<\/b>. <\/span>Covid-19 helped spark a false pandemic<\/b>, and <\/span>spread fear <\/b>across the world, <\/span>to\u00a0 make us accept the Covid-19 vaccines.\u00a0\u00a0<\/b><\/p>\n

Numerical tracing <\/span>nanoparticles <\/b>have been <\/span>added to the vials of the final Covid-19 vaccine (ChAdOx1 nCoV-19)<\/b>.\u00a0<\/span><\/p>\n

By seeking to vaccinate the entire world population<\/b>, the promoters of the Covid-19 vaccines pursue <\/span>two objectives<\/b>:\u00a0<\/span><\/p>\n

– <\/span>Control the entire world population <\/b>after having vaccinated it, <\/span>thanks to the deployment of 5G<\/b>, because these vaccines contain <\/span>nanoparticles <\/b>which will allow the <\/span>identification <\/b>and <\/span>permanent control <\/b>of vaccinated individuals; – <\/span>Limit the world’s population<\/b>.<\/span><\/p>\n\n\n\n
From Sars-CoV<\/span>\u00a0<\/span><\/p>\n

to<\/span>\u00a0<\/span><\/p>\n

Covid-19<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Doctor Fr\u00e9d\u00e9ric Tangy is the father of the Covid-19\u00a0 <\/b><\/p>\n

Doctor Fr\u00e9d\u00e9ric Tangy\u00a0\u00a0<\/b><\/p>\n

Director of Vaccine Innovation at the Institut Pasteur\u00a0<\/span><\/p>\n

Publications related to coronaviruses and vaccines<\/span>\u00a0<\/span><\/p>\n

1- 2003: <\/b>Inventor in Patents EP 1 694 829 B1 and US 012.8224 A1\u00a0<\/span><\/p>\n

2- 2005: <\/b>Publication: Fr\u00e9d\u00e9ric TANGY and Hussein Y. Naim. Live Attenuated Measles Vaccine as a Potential\u00a0 Multivalent Pediatric Vaccination Vector.\u00a0\u00a0<\/span><\/p>\n

\u00a0VIRAL IMMUNOLOGY, Volume 18, Number 2, 2005, page 317-326\u00a0<\/span><\/p>\n

3- 2011<\/b>: Inventor in Patent US 8,343,718 B2\u00a0<\/span><\/p>\n

4- 2014<\/b>: Publication: Nicolas Escriou, ,Beno\u00eet Callendret, Val\u00e9rie Lorin, Chantal Combredet, Philippe\u00a0 Marianneau, Mich\u00e8le F\u00e9vrier, Fr\u00e9d\u00e9ric Tangy. Protection contre le coronavirus du SRAS conf\u00e9r\u00e9e\u00a0 par le vaccin vivant contre la rougeole exprimant la glycoprot\u00e9ine de pointe.\u00a0\u00a0<\/span><\/p>\n

\u00a0Virology, Volumes 452\u2013453, March 2014, page 32-41\u00a0<\/span><\/p>\n

5- 2020: Paris-Match article from April 9-15, 2020\u00a0<\/span><\/p>\n

6- 2020: Paris-Match article from May 14-20, 2020\u00a0<\/span><\/p>\n

Doctor Fr\u00e9d\u00e9ric Tangy is the father of the Covid-19<\/span><\/p>\n

Fr\u00e9d\u00e9ric Tangy<\/span>\u00a0<\/span><\/p>\n

COVID-19 is an artificial coronavirus made in France by the Institut Pasteur from natural Sars-CoV coronavirus\u00a0<\/b><\/p>\n

Covid-19 <\/b>is the <\/span>result of several genetic manipulations <\/b>of a strain of Coronavirus <\/span>Sars-CoV,\u00a0 <\/b>associated with severe acute respiratory syndrome (SARS), <\/span>resulting from a sample\u00a0 <\/b>listed under the number 031589, <\/span>collected from bronchoalveolar washings of Sars\u00a0 infected patients by scientists of Institut Pasteur<\/b>, <\/span>before 2003<\/b>, at the <\/span>French\u00a0 hospital in Hanoi <\/b>(Vietnam)<\/span><\/p>\n

– 1st Step: Sars-CoV-1 <\/b>was produced by a <\/span>first patent <\/b>(<\/span>2003<\/span>: European Patent <\/span>EP1 69 48 29 B1 <\/span>and \u00a0 US Patent <\/span>US 012.8224 A1<\/span>) <\/span>from Sars-CoV <\/b>collected in Hanoi <\/span>before200 3<\/span> – 2nd Step: Sars-CoV-2 <\/b>was <\/span>a continuation of the first US patent <\/b>US 012.8224 A1<\/span>,p rotected \u00a0 by the <\/span>second US Patent <\/b>US 8,243,718 B2 <\/span>(<\/span>2011<\/span>), <\/span>from Sars-CoV-1 <\/b>– 3rd Step: Covid-19 <\/b>was produced <\/span>from Sars-Cov-2 <\/b>by <\/span>inserting <\/b>into its genome <\/span>4 sequences of HIV1 <\/b>(RNA <\/span>AIDS virus<\/b>)\u00a0<\/span><\/p>\n

\u00a0<\/span>Finally\u00a0\u00a0<\/b><\/p>\n

Covid-19 <\/b>was <\/span>made in France <\/b>by French scientists at the Institut Pasteur from Sars-CoV, <\/span>then\u00a0 transferred to Wuhan <\/b>where the <\/span>French scientists of Institut Pasteur do let it escape<\/b>,\u00a0 <\/span>unbeknownst<\/b> to scientists in <\/span>the Wuhan laboratory and the Chinese government\u00a0<\/b><\/p>\n

When she says: “Covid-19 is not a Chinese virus”, CHINA DOES NOT LIE!\u00a0<\/b><\/p>\n\n\n\n
From Sars-CoV<\/span>\u00a0<\/span><\/p>\n

to<\/span>\u00a0<\/span><\/p>\n

Sars-CoV1<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

From Sars-CoV to Sars-CoV1\u00a0 <\/span>2003\u00a0<\/b><\/p>\n

Institut Pasteur Fr\u00e9d\u00e9ric Tangy\u00a0<\/span><\/p>\n

\u00a0<\/span>1 DNA sequence of 29746 nucleotides\u00a0<\/b><\/p>\n

+ 157 DNA and PRT sequences\u00a0<\/b><\/p>\n

inserted into RNA genome of Sars-CoV<\/b><\/p>\n

Sars-CoV <\/b>Sars-CoV1\u00a0<\/b><\/p>\n

Collected at French Hospital of Hanoi,\u00a0\u00a0<\/b><\/p>\n

by Institut Pasteur (sample n\u00b0 031589) <\/b>Patent EP 1 694 829 B1\u00a0<\/b><\/p>\n

Patent US 012.8224 A1\u00a0<\/b>
\n<\/b><\/p>\n

First Patent US 2007\/0128224 A1<\/b><\/p>\n

Patent US 2007\/0128224 A1\u00a0<\/b><\/p>\n

Claims 1<\/b><\/p>\n

Patent US 2007\/0128224 A1\u00a0<\/b><\/p>\n

Claims 2<\/b><\/p>\n

Insertion of a first DNA sequence (29746 nucleotides) in the genome of Sars-Cov collected in the French hospital at Hanoi (Vietnam)<\/b>
\n<\/b><\/p>\n

Listing of the 158 DNA and Protein sequences inserted, by Pasteur Institute people, into the Sars-CoV coronavirus, taken, in 2003, fr<\/b>om a patient at the French hospital in Hanoi\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 1\u00a0<\/b><\/p>\n

DNA\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 2\u00a0<\/b><\/p>\n

DNA<\/b><\/p>\n

Listing of the 158 DNA and Protein sequences inserted, by Pasteur Institute people,\u00a0 into the Sars-CoV coronavirus, taken, in 2003, from a patient at the French hospital in Hanoi <\/b>F<\/b>ollowi<\/b>n<\/b>g up <\/b>\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 3\u00a0<\/b><\/p>\n

PRT\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 16\u00a0<\/b><\/p>\n

DNA\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 28\u00a0<\/b><\/p>\n

PRT<\/b><\/p>\n

Listing of the 158 DNA and Protein sequences inserted, by Pasteur Institute people,\u00a0 into the Sars-CoV coronavirus, taken, in 2003, from a patient at the French hospital in Hanoi\u00a0 <\/b>F<\/b>ollowing up <\/b>\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 31\u00a0<\/b><\/p>\n

DNA\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 46\u00a0<\/b><\/p>\n

DNA\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 55\u00a0<\/b><\/p>\n

DNA<\/b><\/p>\n

Listing of the 158 DNA and Protein sequences inserted, by Pasteur Institute people,\u00a0 into the Sars-CoV coronavirus, taken, in 2003, from a patient at the French hospital in Hanoi\u00a0 <\/b>F<\/b>ollowing up\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 61\u00a0<\/b><\/p>\n

DNA\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 69\u00a0<\/b><\/p>\n

PRT\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 7<\/b>3\u00a0<\/b><\/p>\n

DNA\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 74\u00a0<\/b><\/p>\n

PR<\/b>T\u00a0<\/b><\/p>\n

Listing of the 158 DNA and Protein sequences inserted, by Pasteur Institute people, into\u00a0 the Sars-CoV coronavirus, taken, in 2003, from a patient at the French hospital in Hanoi\u00a0 <\/b>F<\/b>ollowing up\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 88\u00a0<\/b><\/p>\n

DNA\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 89\u00a0<\/b><\/p>\n

DNA\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 90\u00a0<\/b><\/p>\n

DNA\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 91\u00a0<\/b><\/p>\n

DNA\u00a0<\/b><\/p>\n

Listing of the 158 DNA and Protein sequences inserted, by Pasteur Institute people, into\u00a0 the Sars-CoV coronavirus, taken, in 2003, from a patient at the French hospital in Hanoi\u00a0 <\/b>F<\/b>ollowi<\/b>n<\/b>g up\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 121\u00a0<\/b><\/p>\n

DNA\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 122\u00a0<\/b><\/p>\n

DNA\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 12<\/b>3\u00a0<\/b><\/p>\n

DNA\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 124\u00a0<\/b><\/p>\n

DNA\u00a0<\/b><\/p>\n

Listing of the 158 DNA and Protein sequences inserted, by Pasteur Institute people, into\u00a0 the Sars-CoV coronavirus, taken, in 2003, from a patient at the French hospital in Hanoi\u00a0 <\/b>F<\/b>ollowi<\/b>n<\/b>g up\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 140\u00a0<\/b><\/p>\n

DNA\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 157\u00a0<\/b><\/p>\n

DNA\u00a0<\/b><\/p>\n

Sars-CoV1: SEQUENCE 158\u00a0<\/b><\/p>\n

DNA\u00a0<\/b>
\n<\/b><\/p>\n

 <\/p>\n\n\n\n
From Sars-CoV1 <\/span>\u00a0<\/span><\/p>\n

to<\/span>\u00a0<\/span><\/p>\n

Sars-CoV2<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

From Sars-CoV1 to Sars-CoV2 <\/span>2011\u00a0<\/b><\/p>\n

Institut Pasteur\u00a0<\/span><\/p>\n

Fr\u00e9d\u00e9ric Tangy\u00a0<\/span>
\n<\/span><\/p>\n

Sars-CoV1\u00a0<\/b><\/p>\n

Produced by inserting 1 DNA sequence\u00a0 (29746 nucleotides) + 157 DNA and PRT\u00a0 sequences into the Sars-CoV RNA genome\u00a0<\/span><\/p>\n

CONTINUATION OF\u00a0<\/b><\/p>\n

Patent EP 1 694 829 B1\u00a0\u00a0<\/b><\/p>\n

Patent US 012.8224 A1<\/b><\/p>\n

Patent US 8,243,<\/b>7<\/span>18 B2\u00a0\u00a0<\/b><\/p>\n

Sars-CoV2\u00a0<\/b>
\n<\/b><\/p>\n

Patent US 8,243,718 B2 <\/b>continuation of <\/b>First Patent US 2007\/012.8224 A1 <\/b>
\n<\/b><\/p>\n

 <\/p>\n\n\n\n
From Sars-CoV2<\/span>\u00a0<\/span><\/p>\n

to<\/span>\u00a0<\/span><\/p>\n

Covid-19<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

From Sars-CoV2 to Covid-19 <\/span>2019\u00a0<\/b><\/p>\n

Institut Pasteur Fr\u00e9d\u00e9ric Tangy\u00a0<\/span><\/p>\n

Insertion of 4 fragments of HIV1,\u00a0<\/b><\/p>\n

corresponding to short segments of a. a..\u00a0\u00a0<\/span><\/p>\n

found in the gp 120 and the Gag of HIV1,\u00a0<\/b><\/p>\n

in the Sars-CoV2 genome\u00a0<\/span><\/p>\n

Sars-CoV2 Covid-19\u00a0<\/b><\/p>\n

Patent filed in 2019\u00a0\u00a0<\/b><\/p>\n

International Publication date in 2021\u00a0<\/b><\/p>\n

Transformation of Sars-CoV-2 into Covid-19\u00a0<\/b><\/p>\n

The <\/span>Sars-CoV-2 <\/b>coronavirus, described in <\/span>US Patent 8,343,718 B2 <\/b>, is an RNA virus into the\u00a0 genome of which <\/span>DNA sequences<\/b>, <\/span>but not RNA sequences<\/b>, have been inserted.\u00a0<\/span><\/p>\n

Recently, and simultaneously, <\/span>Professor Luc Montagnier <\/b>and a <\/span>group of Indian scientists\u00a0 <\/b>have <\/span>analyzed <\/b>and <\/span>decrypted <\/b>the <\/span>complete genome of the Covid-19 <\/b>coronavirus responsible\u00a0 for the pandemic.\u00a0\u00a0<\/span><\/p>\n

They found in the Covid-19 genome:\u00a0\u00a0<\/span><\/p>\n

– <\/span>sequences of HIV<\/b>, the <\/span>AIDS virus <\/b>(<\/span>4 fragments of HIV1 RNA which correspond to short\u00a0 segments of amino acids found in the gp120 and the Gag of HIV1<\/span>);\u00a0\u00a0<\/span><\/p>\n

– and <\/span>DNA sequences <\/b>from the <\/span>malaria <\/b>germ.\u00a0<\/span><\/p>\n

These results have been published and confirmed by <\/span>Professor Peter Chumakov<\/b>, a well-known\u00a0 Russian microbiologist, and Japanese <\/span>Professor Tasuku Honjo<\/b>, 2018 Nobel Prize laureate in\u00a0 medicine. <\/span>Since there was no RNA sequence in Sars-CoV-2 <\/b>described in <\/span>US Patent\u00a0 8,343,718 B2<\/b>, this analysis proves that <\/span>Covid-19 is the result of genetic manipulation of\u00a0 Sars-CoV-2 <\/b>by <\/span>French scientists from the Institut Pasteur.\u00a0<\/b><\/p>\n

Interview with professor Luc Montagnier by doctor Jean-Fran\u00e7ois Lemoine\u00a0 Health site: Medical Frequency and Why Doctor\u00a0\u00a0<\/span><\/p>\n

(Thursday April 16, 2020)\u00a0\u00a0<\/span><\/p>\n

To read this interview, see <\/span>DOCUMENT 1<\/span><\/p>\n

To read the full article see <\/b>DOCUMENT 2<\/b><\/p>\n

VIRAL IMMUNOLOGY, Volume 18, Number 2,\u00a0\u00a0<\/span><\/p>\n

2005 \u00a9 Mary Ann Liebert, Inc.\u00a0\u00a0<\/span><\/p>\n

Pages 317-326\u00a0\u00a0<\/span><\/p>\n

Review\u00a0\u00a0<\/span><\/p>\n

Live Attenuated Measles Vaccine\u00a0\u00a0<\/b><\/p>\n

as a Potential Multivalent Pediatric Vaccination Vector\u00a0\u00a0<\/b><\/p>\n

FR\u00c9D\u00c9RIC TANGY<\/b>1<\/b>and HUSSEIN Y. NAIM<\/b>2<\/b>\u00a0<\/b><\/p>\n

(1- Unit\u00e9 des Virus Lents, CNRS URA 1930, Institut Pasteur, Paris, France. 2- Berna Biotech LTD, Rehhagstrasse 79, 3018 Bern, Switzerland)\u00a0<\/span><\/p>\n

A<\/span>BSTRACT<\/span>\u00a0<\/span><\/p>\n

Live attenuated RNA viruses make highly efficient vaccines. Among them <\/span>is the <\/span>live attenuated<\/b>\u00a0 <\/b>measles virus (MV<\/b>) vaccine <\/b>that has been given to a very large number of children and has been shown\u00a0 to be highly efficacious and safe. MV vaccine induces a life-long immunity after a single injection or\u00a0 two low-dose injections. It is easily produced on a large scale in most countries and can be distributed at low\u00a0 cost. Reversion to pathogenicity bas never been observed with this vaccine. For all of these\u00a0 <\/span>characteristics, <\/span>developing of MV vaccine vector as a multivalent vaccine to immunize children<\/b>\u00a0 <\/b>against both measles and other infectious agents such as h<\/b>uman immuno<\/b>deficiency<\/b> virus (HIV),\u00a0 flaviviruses, or malaria <\/b>might be very promising for worldwide use. As MV vaccine is inexpensive to\u00a0 produce, the generation of recombinant vaccines may remain affordable and attractive for the\u00a0 <\/span>developing world. In this a<\/span>rticle, we describe the <\/span>development of MV<\/b> vector and present some<\/b>\u00a0 <\/b>recent data showing the capacity of recomb<\/b>inant MV vaccine to express various proteins from HIV\u00a0 and West Nile virus<\/b>. In addition, the ability of recombinant MV to induce specific immune responses\u00a0 against these different pathogens are presented and discussed.\u00a0<\/span><\/p>\n

Interview with Doctor Fr\u00e9d\u00e9ric Tangy\u00a0\u00a0<\/span><\/p>\n

Paris-Match article from April 9-15, 2020\u00a0\u00a0<\/span><\/p>\n

To read this interview\u00a0\u00a0<\/span><\/p>\n

See <\/span>DOCUMENT 3<\/span> (Original) and <\/span>DOCUMENT 4<\/span> (English traduction)<\/span><\/p>\n

Elaboration of Covid-19 vaccine according to Dr Fr\u00e9d\u00e9ric Tangy\u00a0<\/b><\/p>\n

The complete and detailed \u00abrecipe\u00bb for one Covid 19 vaccine, was given to us by\u00a0 Dr Fr\u00e9d\u00e9ric Tangy, head of Vaccine Innovation at the Institut Pasteur in Paris, in an\u00a0 interview with the newspaper Paris-Match, in the 9-15 edition April 2020 (See\u00a0 <\/span>Documents 3 and 4<\/span>)\u00a0<\/span><\/p>\n

Thus, as explained perfectly to us by Dr. Fr\u00e9d\u00e9ric Tangy – who is decidedly very\u00a0 talkative – <\/span>the spike glycoprotein of Covid-19, which contains the 4 RNA\u00a0 sequences of HIV<\/b>– which is clear from the <\/span>group’s analysis of Indian\u00a0 researchers<\/b>, <\/span>but was hidden <\/b>(like <\/span>DNA sequences of malaria <\/b>genome) by\u00a0 scientists at the Institut Pasteur – <\/span>is intended<\/b>, he said, <\/span>to induce immunity in the\u00a0 vaccine<\/b>, serving as an antigen after insertion into the genome of the attenuated\u00a0 measles virus (who remember it is an RNA virus). But, obviously, it does not tell\u00a0 us that the RNA HIV nucleic acids, which have already been previously inserted\u00a0 into the genome of Sars-CoV2 coronavirus, are those of HIV. And, since it is\u00a0 not in the Sars-CoV-2 coronavirus genome, one wonders where it came from !<\/span><\/p>\n

It should be noted that Dr. Fr\u00e9d\u00e9ric Tangy gave this interview a few days before\u00a0 that of Pr Luc Montagnier\u00a0\u00a0<\/span><\/p>\n\n\n\n
From Covid-19<\/span>\u00a0<\/span><\/p>\n

to<\/span>\u00a0<\/span><\/p>\n

Covid-19 Vaccines<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u00a0<\/span><\/p>\n

From Covid-19 to Covid-19 Vaccines Covid-19\u00a0\u00a0<\/b><\/p>\n

Insertion of Covid-19 genome into\u00a0 the genome of a viral vector\u00a0\u00a0<\/b><\/p>\n

(<\/span>ChAdOx1 chimpanzee DNA adenovirus)\u00a0<\/span><\/p>\n

Jenner\u00a0<\/b><\/p>\n

Institute\u00a0<\/b><\/p>\n

Adrian Hill\u00a0<\/b>
\n<\/b><\/p>\n

Covid-19 vaccines\u00a0<\/b><\/p>\n

ChAdOx1 nCoV-19 <\/b>(<\/b>AstraZeneca, Sanofi<\/b>) <\/b>Insertion of tracing nanoparticles\u00a0\u00a0<\/b>
\n<\/b><\/p>\n

in the vaccine vial to be injected\u00a0 into the human body\u00a0\u00a0<\/b><\/p>\n

together with the vaccine\u00a0\u00a0<\/b><\/p>\n

US Patent WO 2020\/060606 A1\u00a0 PCT\/US20 19\/038084 Microsoft\u00a0<\/b>
\n<\/b><\/p>\n

Final vaccine\u00a0\u00a0<\/b><\/p>\n

Bill Gates\u00a0<\/span><\/p>\n

NANOPARTICLES OF Covid-19 VACCINES\u00a0\u00a0<\/b>
\n<\/b><\/p>\n

Vaccinated people\u00a0<\/b><\/p>\n

Satellites for 5G\u00a0<\/b><\/p>\n

Task server\u00a0<\/b><\/p>\n

Nanoparticles <\/b>5G relays<\/b>\u00a0<\/b><\/p>\n

injected\u00a0\u00a0<\/b><\/p>\n

together with vaccine\u00a0<\/b><\/p>\n

Nanoparticles<\/b><\/p>\n

Mobile phones\u00a0<\/b>
\n<\/b><\/p>\n

Bill Gates\u00a0<\/span><\/p>\n

Nanoparticles and the permanent control of vaccinated people\u00a0<\/b><\/p>\n

The <\/span>nanoparticles <\/b>described in the Microsoft patent (<\/span>US Patent WO 2020\/060606 A1)\u00a0 <\/span>are <\/span>sensors <\/b>which <\/span>must be diffused in the body of the vaccinated person<\/b>, <\/span>in order <\/b>to be able <\/span>to detect it\u00a0<\/b><\/p>\n

Introduced into the vaccine vial, <\/span>they are injected into the body, together with the vaccine<\/b>, at the time of vaccination\u00a0\u00a0<\/span><\/p>\n

Once they are in the body, they cannot be gotten rid of<\/b>, unlike a subcutaneous digital\u00a0 tracing microchip. From this moment, <\/span>the vaccinated people will be detectable by any mobile phone located nearby<\/b>.\u00a0\u00a0<\/span><\/p>\n

Mobile phones <\/b>are <\/span>connected to the internet by 5G\u00a0<\/b><\/p>\n

5G relays <\/b>allow this <\/span>communication <\/b>through <\/span>satellites 5G<\/b>.\u00a0<\/span><\/p>\n

The vaccinated people will have lost definitely all freedom in their existence\u00a0<\/b><\/p>\n

Are 160 Covid-19 vaccines really in development?\u00a0\u00a0<\/b><\/p>\n

According to information provided by the NIH and WHO,\u00a0 160 vaccines against Covid-19 are under development\u00a0\u00a0<\/b><\/p>\n

The list of the 160 candidates for Covid-19 vaccines in\u00a0 development was compiled by the NIH\u00a0<\/b><\/p>\n

Of these160 candidates\u00a0\u00a0<\/b><\/p>\n

only 21 clinical study protocols\u00a0\u00a0<\/b><\/p>\n

have been written by the NIH\u00a0<\/b>
\n<\/b><\/p>\n

List of candidates for Covid-19 vaccines in development <\/b>DRAFT landscape of COVID-19 candidate vaccines \u2013 7 July 2020\u00a0 <\/span>21 candidate vaccines in clinical evaluation<\/b>\u00a0<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Platform\u00a0<\/b><\/td>\nType of\u00a0\u00a0<\/b><\/p>\n

candidate\u00a0\u00a0<\/b><\/p>\n

vaccine<\/b><\/td>\n

Developer\u00a0<\/b><\/td>\nCoronavirus\u00a0 target<\/b><\/td>\nCurrent stage of clinical\u00a0\u00a0<\/b><\/p>\n

evaluation\/regulatory status Coronavirus candidate<\/b><\/td>\n

Same platform for\u00a0 non-Coronavirus\u00a0 candidates<\/b><\/td>\n<\/tr>\n
Inactivated\u00a0<\/span><\/td>\nInactivated +\u00a0\u00a0<\/span><\/p>\n

alum<\/span><\/td>\n

Sinovac\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPhase 3\u00a0<\/span><\/p>\n

NCT04456595<\/span>\u00a0<\/span><\/p>\n

Phase 1\/2\u00a0<\/span><\/p>\n

NCT04383574<\/span>\u00a0<\/span><\/p>\n

NCT04352608<\/span><\/td>\n

SARS<\/span><\/td>\n<\/tr>\n
Non\u00a0<\/span><\/p>\n

Replicating\u00a0\u00a0<\/span><\/p>\n

Viral Vector<\/span><\/td>\n

ChAdOx1-S\u00a0<\/span><\/td>\nUniversity of\u00a0\u00a0<\/span><\/p>\n

Oxford\/AstraZeneca<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPhase 3\u00a0<\/span><\/p>\n

ISRCTN89951424<\/span>\u00a0<\/span><\/p>\n

Phase2b\/3\u00a0<\/span><\/p>\n

2020-001228-32<\/span>\u00a0<\/span><\/p>\n

Phase 1\/2\u00a0<\/span><\/p>\n

PACTR202006922165132<\/span>\u00a0<\/span><\/p>\n

2020-001072-15<\/span><\/td>\n

MERS, influenza,\u00a0 TB, Chikungunya,\u00a0 Zika, MenB, plague<\/span><\/td>\n<\/tr>\n
Non\u00a0<\/span><\/p>\n

Replicating\u00a0\u00a0<\/span><\/p>\n

Viral Vector<\/span><\/td>\n

Adenovirus Type\u00a0 5 Vector<\/span><\/td>\nCanSino Biological\u00a0\u00a0<\/span><\/p>\n

Inc.\/Beijing Institute of\u00a0 Biotechnology<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPhase 2\u00a0<\/span><\/p>\n

ChiCTR2000031781<\/span>\u00a0<\/span><\/p>\n

Phase 1\u00a0<\/span><\/p>\n

ChiCTR2000030906<\/span><\/td>\n

Ebola<\/span><\/td>\n<\/tr>\n
RNA\u00a0<\/span><\/td>\nLNP\u00a0<\/span><\/p>\n

encapsulated\u00a0\u00a0<\/span><\/p>\n

mRNA<\/span><\/td>\n

Moderna\/NIAID\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPhase 2\u00a0<\/span><\/p>\n

NCT04405076<\/span>\u00a0<\/span><\/p>\n

Phase 1\u00a0<\/span><\/p>\n

NCT04283461<\/span><\/td>\n

multiple candidates<\/span><\/td>\n<\/tr>\n
DNA\u00a0<\/span><\/td>\nDNA plasmid\u00a0\u00a0<\/span><\/p>\n

vaccine with\u00a0<\/span><\/p>\n

electroporation\u00a0<\/span><\/td>\n

Inovio Pharmaceuticals\/ International Vaccine\u00a0\u00a0<\/span><\/p>\n

Institute<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPhase 1\/2\u00a0<\/span><\/p>\n

NCT04447781<\/span>\u00a0<\/span><\/p>\n

NCT04336410<\/span><\/td>\n

multiple candidates<\/span><\/td>\n<\/tr>\n
DNA\u00a0<\/span><\/td>\nDNA plasmid\u00a0\u00a0<\/span><\/p>\n

vaccine\u00a0<\/span><\/td>\n

Cadila Healthcare Limited\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPhase 1\/2\u00a0<\/span><\/p>\n

CTRI\/2020\/07\/026352<\/span>\u00a0<\/span><\/p>\n

(not yet recruiting)<\/span><\/td>\n

<\/td>\n<\/tr>\n
Inactivated\u00a0<\/span><\/td>\nInactivated\u00a0<\/span><\/td>\nWuhan Institute of\u00a0\u00a0<\/span><\/p>\n

Biological\u00a0\u00a0<\/span><\/p>\n

Products\/Sinopharm<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPhase 1\/2\u00a0<\/span><\/p>\n

ChiCTR2000031809<\/span><\/td>\n

<\/td>\n<\/tr>\n
Inactivated\u00a0<\/span><\/td>\nInactivated\u00a0<\/span><\/td>\nBeijing Institute of\u00a0\u00a0<\/span><\/p>\n

Biological\u00a0\u00a0<\/span><\/p>\n

Products\/Sinopharm<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPhase 1\/2\u00a0\u00a0<\/span><\/p>\n

ChiCTR2000032459<\/span><\/td>\n

<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Full length\u00a0\u00a0<\/span><\/p>\n

recombinant\u00a0\u00a0<\/span><\/p>\n

SARS CoV-2\u00a0\u00a0<\/span><\/p>\n

glycoprotein\u00a0\u00a0<\/span><\/p>\n

nanoparticle\u00a0\u00a0<\/span><\/p>\n

vaccine\u00a0\u00a0<\/span><\/p>\n

adjuvanted with\u00a0 Matrix M<\/span><\/td>\n

Novavax\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPhase 1\/2\u00a0<\/span><\/p>\n

NCT04368988<\/span><\/td>\n

RSV; CCHF, HPV,\u00a0 VZV, EBOV<\/span><\/td>\n<\/tr>\n
RNA\u00a0<\/span><\/td>\n3 LNP-mRNAs\u00a0<\/span><\/td>\nBioNTech\/Fosun\u00a0\u00a0<\/span><\/p>\n

Pharma\/Pfizer<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPhase 1\/2\u00a0<\/span><\/p>\n

2020-001038-36<\/span>\u00a0<\/span><\/p>\n

NCT04368728<\/span><\/td>\n

<\/td>\n<\/tr>\n
DNA\u00a0<\/span><\/td>\nDNA Vaccine\u00a0\u00a0<\/span><\/p>\n

(GX-19)<\/span><\/td>\n

Genexine Consortium\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPhase 1\u00a0<\/span><\/p>\n

NCT04445389<\/span><\/td>\n

<\/td>\n<\/tr>\n
DNA\u00a0<\/span><\/td>\nDNA plasmid\u00a0\u00a0<\/span><\/p>\n

vaccine +\u00a0\u00a0<\/span><\/p>\n

Adjuvant<\/span><\/td>\n

Osaka University\/ AnGes\/\u00a0 Takara Bio<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPhase 1\u00a0<\/span><\/p>\n

JapicCTI-205328<\/span><\/td>\n

<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

DISCLAIMER<\/b>:\u00a0\u00a0<\/b><\/p>\n

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the\u00a0 novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any\u00a0 approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the\u00a0 information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy,\u00a0 completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and\/or non-infringement of any\u00a0 information provided in these landscape documents and\/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility\u00a0 whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement,\u00a0 distribution or use of any product included in any of these landscape documents.\u00a0\u00a0<\/b><\/p>\n

FOLLOWING\u00a0<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Inactivated\u00a0<\/span><\/td>\nInactivated\u00a0<\/span><\/td>\nInstitute of Medical Biology\u00a0 , Chinese Academy of\u00a0\u00a0<\/span><\/p>\n

Medical Sciences<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPhase 1\u00a0<\/span><\/p>\n

NCT04412538<\/span><\/td>\n

<\/td>\n<\/tr>\n
Non\u00a0<\/span><\/p>\n

Replicating\u00a0\u00a0<\/span><\/p>\n

Viral Vector<\/span><\/td>\n

Adeno-based\u00a0<\/span><\/td>\nGamaleya Research\u00a0\u00a0<\/span><\/p>\n

Institute\u00a0<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPhase 1\u00a0<\/span><\/p>\n

NCT04436471<\/span>\u00a0<\/span><\/p>\n

NCT04437875<\/span><\/td>\n

<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Native like\u00a0\u00a0<\/span><\/p>\n

Trimeric subunit\u00a0 Spike Protein\u00a0\u00a0<\/span><\/p>\n

vaccine<\/span><\/td>\n

Clover Biopharmaceuticals\u00a0 Inc.\/GSK\/Dynavax<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPhase 1\u00a0<\/span><\/p>\n

NCT04405908<\/span><\/td>\n

HIV, REV Influenza<\/span><\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Adjuvanted\u00a0\u00a0<\/span><\/p>\n

recombinant\u00a0\u00a0<\/span><\/p>\n

protein (RBD\u00a0<\/span><\/p>\n

Dimer)<\/span><\/td>\n

Anhui Zhifei Longcom\u00a0\u00a0<\/span><\/p>\n

Biopharmaceutical\/\u00a0<\/span><\/p>\n

Institute of Microbiology,\u00a0 Chinese Academy of\u00a0\u00a0<\/span><\/p>\n

Sciences<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPhase 1\u00a0<\/span><\/p>\n

NCT04445194<\/span><\/td>\n

MERS<\/span><\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Recombinant\u00a0\u00a0<\/span><\/p>\n

spike protein\u00a0\u00a0<\/span><\/p>\n

with Advax™\u00a0\u00a0<\/span><\/p>\n

adjuvant<\/span><\/td>\n

Vaxine Pty Ltd\/Medytox\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPhase 1\u00a0<\/span><\/p>\n

NCT04453852<\/span><\/td>\n

<\/td>\n<\/tr>\n
RNA\u00a0<\/span><\/td>\nLNP-nCoVsaRNA\u00a0<\/span><\/td>\nImperial College London\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPhase 1\u00a0<\/span><\/p>\n

ISRCTN17072692<\/span><\/td>\n

EBOV; LASV, MARV,\u00a0 Inf (H7N9), RABV<\/span><\/td>\n<\/tr>\n
RNA\u00a0<\/span><\/td>\nmRNA\u00a0<\/span><\/td>\nCurevac\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPhase 1\u00a0<\/span><\/p>\n

NCT04449276<\/span><\/td>\n

RABV, LASV, YFV;\u00a0 MERS, InfA, ZIKV,\u00a0 DENV, NIPV<\/span><\/td>\n<\/tr>\n
RNA\u00a0<\/span><\/td>\nmRNA\u00a0<\/span><\/td>\nPeople’s Liberation Army\u00a0 (PLA) Academy of Military\u00a0 Sciences\/Walvax Biotech.<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPhase 1\u00a0<\/span><\/p>\n

ChiCTR2000034112<\/span><\/td>\n

<\/td>\n<\/tr>\n
VLP\u00a0<\/span><\/td>\nPlant-derived\u00a0\u00a0<\/span><\/p>\n

VLP<\/span><\/td>\n

Medicago Inc.\/ Universit\u00e9\u00a0 Laval<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPhase 1\u00a0<\/span><\/p>\n

NCT04450004<\/span>\u00a0<\/span><\/p>\n

(not yet recruiting)<\/span><\/td>\n

Flu, Rotavirus,\u00a0\u00a0<\/span><\/p>\n

Norovirus, West\u00a0 Nile virus, Cancer<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

FOLLOWING\u00a0<\/b><\/p>\n

139 candidate vaccines in preclinical evaluation<\/b>\u00a0<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Platform\u00a0<\/b><\/td>\nType of candidate\u00a0 vaccine<\/b><\/td>\nDeveloper\u00a0<\/b><\/td>\nCoronavirus\u00a0 target<\/b><\/td>\nCurrent stage of clinical\u00a0 evaluation\/regulatory\u00a0 status- Coronavirus\u00a0 candidate<\/b><\/td>\nSame platform\u00a0 for non\u00a0<\/b><\/p>\n

Coronavirus\u00a0\u00a0<\/b><\/p>\n

candidates<\/b><\/td>\n<\/tr>\n

DNA\u00a0<\/span><\/td>\nDNA vaccine\u00a0<\/span><\/td>\nEge University\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
DNA\u00a0<\/span><\/td>\nDNA plasmid vaccine\u00a0 RBD&N<\/span><\/td>\nScancell\/University of Nottingham\/ Nottingham Trent University<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
DNA\u00a0<\/span><\/td>\nDNA plasmid vaccine\u00a0 S,S1,S2,RBD &N<\/span><\/td>\nNational Research Centre, Egypt\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
DNA\u00a0<\/span><\/td>\nDNA with\u00a0\u00a0<\/span><\/p>\n

electroporation<\/span><\/td>\n

Karolinska Institute \/ Cobra\u00a0\u00a0<\/span><\/p>\n

Biologics\u00a0\u00a0<\/span><\/p>\n

(OPENCORONA Project)<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
DNA\u00a0<\/span><\/td>\nDNA with\u00a0\u00a0<\/span><\/p>\n

electroporation<\/span><\/td>\n

Chula Vaccine Research Center\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
DNA\u00a0<\/span><\/td>\nDNA\u00a0<\/span><\/td>\nTakis\/Applied DNA\u00a0\u00a0<\/span><\/p>\n

Sciences\/Evvivax<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
DNA\u00a0<\/span><\/td>\nPlasmid DNA, Needle Free Delivery<\/span><\/td>\nImmunomic Therapeutics,\u00a0\u00a0<\/span><\/p>\n

Inc.\/EpiVax, Inc.\/PharmaJet<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nSARS<\/span><\/td>\n<\/tr>\n
DNA\u00a0<\/span><\/td>\nDNA vaccine\u00a0<\/span><\/td>\nBioNet Asia\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
DNA\u00a0<\/span><\/td>\nmsDNA vaccine\u00a0<\/span><\/td>\nMediphage Bioceuticals\/University\u00a0 of Waterloo<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
DNA\u00a0<\/span><\/td>\nDNA vaccine\u00a0<\/span><\/td>\nEntos Pharmaceuticals\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
DNA\u00a0<\/span><\/td>\nbacTRL-Spike\u00a0<\/span><\/td>\nSymvivo\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Inactivated\u00a0<\/span><\/td>\nInactivated + alum\u00a0<\/span><\/td>\nKM Biologics\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nJE, Zika<\/span><\/td>\n<\/tr>\n
Inactivated\u00a0<\/span><\/td>\nInactivated\u00a0<\/span><\/td>\nSelcuk University\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Inactivated\u00a0<\/span><\/td>\nInactivated whole\u00a0<\/span><\/p>\n

virus<\/span><\/td>\n

National Research Centre, Egypt\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Inactivated\u00a0<\/span><\/td>\nInactivated\u00a0<\/span><\/td>\nBeijing Minhai Biotechnology Co.,\u00a0 Ltd.<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

DISCLAIMER<\/b>:\u00a0\u00a0<\/b><\/p>\n

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the\u00a0 novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any\u00a0 approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the\u00a0 information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy,\u00a0 completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and\/or non-infringement of any\u00a0 information provided in these landscape documents and\/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility\u00a0 whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement,\u00a0 distribution or use of any product included in any of these landscape documents.\u00a0\u00a0<\/b><\/p>\n

FOLLOWING<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Inactivated\u00a0<\/span><\/td>\nTBD\u00a0<\/span><\/td>\nOsaka University\/ BIKEN\/ NIBIOHN\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Inactivated\u00a0<\/span><\/td>\nInactivated + CpG\u00a0\u00a0<\/span><\/p>\n

1018<\/span><\/td>\n

Sinovac\/Dynavax\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Inactivated\u00a0<\/span><\/td>\nInactivated + CpG\u00a0\u00a0<\/span><\/p>\n

1018<\/span><\/td>\n

Valneva\/Dynavax\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Inactivated\u00a0<\/span><\/td>\nInactivated\u00a0<\/span><\/td>\nResearch Institute for Biological\u00a0 Safety Problems, Rep of Kazakhstan<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Live\u00a0\u00a0<\/span><\/p>\n

Attenuated\u00a0 Virus<\/span><\/td>\n

Codon deoptimized\u00a0 live attenuated\u00a0\u00a0<\/span><\/p>\n

vaccines<\/span><\/td>\n

Mehmet Ali Aydinlar University \/\u00a0 Ac\u0131badem Labmed Health Services\u00a0 A.S.<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Live\u00a0\u00a0<\/span><\/p>\n

Attenuated\u00a0 Virus<\/span><\/td>\n

Codon deoptimized\u00a0 live attenuated\u00a0\u00a0<\/span><\/p>\n

vaccines<\/span><\/td>\n

Codagenix\/Serum Institute of India\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nHAV, InfA, ZIKV,\u00a0 FMD, SIV, RSV,\u00a0 DENV<\/span><\/td>\n<\/tr>\n
Live\u00a0\u00a0<\/span><\/p>\n

Attenuated\u00a0 Virus<\/span><\/td>\n

Codon deoptimized\u00a0 live attenuated\u00a0\u00a0<\/span><\/p>\n

vaccines<\/span><\/td>\n

Indian Immunologicals Ltd\/Griffith\u00a0 University<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Non\u00a0<\/span><\/p>\n

Replicating\u00a0 Viral Vector<\/span><\/td>\n

Sendai virus vector\u00a0<\/span><\/td>\nID Pharma\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Non\u00a0<\/span><\/p>\n

Replicating\u00a0 Viral Vector<\/span><\/td>\n

Adenovirus-based\u00a0<\/span><\/td>\nAnkara University\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Non\u00a0<\/span><\/p>\n

Replicating\u00a0 Viral Vector<\/span><\/td>\n

Adeno-associated\u00a0 virus vector\u00a0\u00a0<\/span><\/p>\n

(AAVCOVID)<\/span><\/td>\n

Massachusetts Eye and\u00a0\u00a0<\/span><\/p>\n

Ear\/Massachusetts General\u00a0\u00a0<\/span><\/p>\n

Hospital\/AveXis<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Non\u00a0<\/span><\/p>\n

Replicating\u00a0 Viral Vector<\/span><\/td>\n

MVA encoded VLP\u00a0<\/span><\/td>\nGeoVax\/BravoVax\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nLASV, EBOV,\u00a0\u00a0<\/span><\/p>\n

MARV, HIV<\/span><\/td>\n<\/tr>\n

Non\u00a0<\/span><\/p>\n

Replicating\u00a0 Viral Vector<\/span><\/td>\n

Ad26\u00a0<\/span><\/td>\nJanssen Pharmaceutical Companies\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nEbola, HIV, RSV<\/span><\/td>\n<\/tr>\n
Non\u00a0<\/span><\/p>\n

Replicating\u00a0 Viral Vector<\/span><\/td>\n

Replication defective\u00a0 Simian Adenovirus\u00a0 (GRAd) encoding\u00a0\u00a0<\/span><\/p>\n

SARS-CoV-2 S<\/span><\/td>\n

ReiThera\/LEUKOCARE\/Univercells\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Non\u00a0<\/span><\/p>\n

replicating\u00a0 viral vector<\/span><\/td>\n

MVA-S encoded\u00a0<\/span><\/td>\nDZIF \u2013 German Center for Infection\u00a0 Research\/IDT Biologika GmbH<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-clinical\u00a0<\/span><\/td>\nMany<\/span><\/td>\n<\/tr>\n
Non\u00a0<\/span><\/p>\n

replicating\u00a0 viral vector<\/span><\/td>\n

MVA-S\u00a0<\/span><\/td>\nIDIBAPS-Hospital Clinic, Spain\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Non\u00a0<\/span><\/p>\n

Replicating\u00a0 Viral Vector<\/span><\/td>\n

adenovirus-based\u00a0 NasoVAX expressing\u00a0 SARS2-CoV spike\u00a0\u00a0<\/span><\/p>\n

protein<\/span><\/td>\n

Altimmune\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\ninfluenza<\/span><\/td>\n<\/tr>\n
Non\u00a0<\/span><\/p>\n

Replicating\u00a0 Viral Vector<\/span><\/td>\n

[E1-, E2b-, E3-] hAd5- COVID19-\u00a0<\/span><\/p>\n

Spike\/Nucleocapsid<\/span><\/td>\n

ImmunityBio, Inc. & NantKwest,\u00a0 Inc.<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nflu, Chik, Zika,\u00a0 EBOV, LASV,\u00a0\u00a0<\/span><\/p>\n

HIV\/SIV,Cancer<\/span><\/td>\n<\/tr>\n

Non\u00a0<\/span><\/p>\n

Replicating\u00a0 Viral Vector<\/span><\/td>\n

Ad5 S (GREVAX™\u00a0\u00a0<\/span><\/p>\n

platform)<\/span><\/td>\n

Greffex\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nMERS<\/span><\/td>\n<\/tr>\n
Non\u00a0<\/span><\/p>\n

Replicating\u00a0 Viral Vector<\/span><\/td>\n

Oral Ad5 S\u00a0<\/span><\/td>\nStabilitech Biopharma Ltd\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nZika, VZV, HSV-2\u00a0 and Norovirus<\/span><\/td>\n<\/tr>\n
Non\u00a0<\/span><\/p>\n

Replicating\u00a0 Viral Vector<\/span><\/td>\n

adenovirus-based +\u00a0 HLA-matched\u00a0\u00a0<\/span><\/p>\n

peptides<\/span><\/td>\n

Valo Therapeutics Ltd\u00a0<\/span><\/td>\nPan-Corona\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Non\u00a0<\/span><\/p>\n

Replicating\u00a0 Viral Vector<\/span><\/td>\n

Oral Vaccine platform\u00a0<\/span><\/td>\nVaxart\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nInfA, CHIKV,\u00a0\u00a0<\/span><\/p>\n

LASV, NORV;\u00a0\u00a0<\/span><\/p>\n

EBOV, RVF, HBV,\u00a0 VEE<\/span><\/td>\n<\/tr>\n

Non\u00a0<\/span><\/p>\n

Replicating\u00a0 Viral Vector<\/span><\/td>\n

MVA expressing\u00a0\u00a0<\/span><\/p>\n

structural proteins<\/span><\/td>\n

Centro Nacional Biotecnolog\u00eda\u00a0 (CNB-CSIC), Spain<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nMultiple\u00a0\u00a0<\/span><\/p>\n

candidates<\/span><\/td>\n<\/tr>\n

Non\u00a0<\/span><\/p>\n

Replicating\u00a0 Viral Vector<\/span><\/td>\n

Dendritic cell-based\u00a0 vaccine<\/span><\/td>\nUniversity of Manitoba\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

DISCLAIMER<\/b>:\u00a0\u00a0<\/b><\/p>\n

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the\u00a0 novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any\u00a0 approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the\u00a0 information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy,\u00a0 completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and\/or non-infringement of any\u00a0 information provided in these landscape documents and\/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility\u00a0 whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement,\u00a0 distribution or use of any product included in any of these landscape documents.\u00a0\u00a0<\/b><\/p>\n

FOLLOWING<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Non\u00a0<\/span><\/p>\n

Replicating\u00a0 Viral Vector<\/span><\/td>\n

parainfluenza virus 5\u00a0 (PIV5)-based vaccine\u00a0 expressing the spike\u00a0 protein<\/span><\/td>\nUniversity of Georgia\/University of\u00a0 Iowa<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nMERS<\/span><\/td>\n<\/tr>\n
Non\u00a0<\/span><\/p>\n

Replicating\u00a0 Viral Vector<\/span><\/td>\n

Recombinant\u00a0\u00a0<\/span><\/p>\n

deactivated rabies\u00a0 virus containing S1<\/span><\/td>\n

Bharat Biotech\/Thomas Jefferson\u00a0 University<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nHeV, NiV, EBOV,\u00a0 LASSA, CCHFV,\u00a0 MERS<\/span><\/td>\n<\/tr>\n
Non\u00a0<\/span><\/p>\n

Replicating\u00a0 Viral Vector<\/span><\/td>\n

Influenza A H1N1\u00a0\u00a0<\/span><\/p>\n

vector<\/span><\/td>\n

National Research Centre, Egypt\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Non\u00a0<\/span><\/p>\n

Replicating\u00a0 Viral Vector<\/span><\/td>\n

Inactivated Flu-based\u00a0 SARS-CoV2 vaccine +\u00a0 Adjuvant<\/span><\/td>\nNational Center for Genetic\u00a0\u00a0<\/span><\/p>\n

Engineering and Biotechnology\u00a0 (BIOTEC) \/GPO, Thailand\u00a0<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Recombinant S\u00a0\u00a0<\/span><\/p>\n

protein<\/span><\/td>\n

Izmir Biomedicine and Genome\u00a0 Center<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Peptide + novel\u00a0\u00a0<\/span><\/p>\n

adjuvant<\/span><\/td>\n

Bogazici University\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

S subunit intranasal\u00a0 liposomal formulation\u00a0 with GLA\/3M052 adjs.<\/span><\/td>\nUniversity of Virginia\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Subunit\u00a0<\/span><\/td>\nHelix Biogen Consult, Ogbomoso &\u00a0 Trinity Immonoefficient Laboratory,\u00a0 Ogbomoso, Oyo State, Nigeria.<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Protein Subunit\u00a0\u00a0<\/span><\/p>\n

S,N,M&S1 protein<\/span><\/td>\n

National Research Centre, Egypt\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Protein Subunit\u00a0<\/span><\/td>\nUniversity of San Martin and\u00a0 CONICET, Argentina<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

RBD protein fused\u00a0 with Fc of IgG + Adj.<\/span><\/td>\nChulalongkorn University\/GPO,\u00a0 Thailand<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Capsid-like Particle\u00a0<\/span><\/td>\nAdaptVac (PREVENT-nCoV\u00a0\u00a0<\/span><\/p>\n

consortium)<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Drosophila S2 insect\u00a0 cell expression system VLPs<\/span><\/td>\nExpreS2ion\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Peptide antigens\u00a0\u00a0<\/span><\/p>\n

formulated in LNP<\/span><\/td>\n

IMV Inc\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

S protein\u00a0<\/span><\/td>\nWRAIR\/USAMRIID\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

S protein +Adjuvant\u00a0<\/span><\/td>\nNational Institute of Infectious\u00a0 Disease, Japan\/Shionogi\/UMN\u00a0 Pharma<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nInfluenza<\/span><\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

VLP-recombinant\u00a0\u00a0<\/span><\/p>\n

protein + Adjuvant<\/span><\/td>\n

Osaka University\/ BIKEN\/ National\u00a0 Institutes of Biomedical Innovation,\u00a0 Japan<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

microneedle arrays S1\u00a0 subunit<\/span><\/td>\nUniv. of Pittsburgh\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nMERS<\/span><\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Peptide\u00a0<\/span><\/td>\nVaxil Bio\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Adjuvanted protein\u00a0 subunit (RBD)<\/span><\/td>\nBiological E Ltd\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Peptide\u00a0<\/span><\/td>\nFlow Pharma Inc\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nEbola, Marburg,\u00a0 HIV, Zika,\u00a0\u00a0<\/span><\/p>\n

Influenza, HPV\u00a0 therapeutic\u00a0\u00a0<\/span><\/p>\n

vaccine,\u00a0\u00a0<\/span><\/p>\n

BreastCA\u00a0\u00a0<\/span><\/p>\n

vaccine<\/span><\/td>\n<\/tr>\n

Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

S protein\u00a0<\/span><\/td>\nAJ Vaccines\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Ii-Key peptide\u00a0<\/span><\/td>\nGenerex\/EpiVax\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nInfluenza, HIV,\u00a0 SARS-CoV<\/span><\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

S protein\u00a0<\/span><\/td>\nEpiVax\/Univ. of Georgia\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nH7N9<\/span><\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Protein Subunit EPV CoV-19<\/span><\/td>\nEpiVax\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

S protein (baculovirus\u00a0 production)<\/span><\/td>\nSanofi Pasteur\/GSK\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nInfluenza, SARS CoV<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

DISCLAIMER<\/b>:\u00a0\u00a0<\/b><\/p>\n

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the\u00a0 novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any\u00a0 approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the\u00a0 information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy,\u00a0 completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and\/or non-infringement of any\u00a0 information provided in these landscape documents and\/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility\u00a0 whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement,\u00a0 distribution or use of any product included in any of these landscape documents.\u00a0\u00a0<\/b><\/p>\n

FOLLOWING<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

gp-96 backbone\u00a0<\/span><\/td>\nHeat Biologics\/Univ. Of Miami\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nNSCLC, HIV,\u00a0\u00a0<\/span><\/p>\n

malaria, Zika<\/span><\/td>\n<\/tr>\n

Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Molecular clamp\u00a0\u00a0<\/span><\/p>\n

stabilized Spike\u00a0\u00a0<\/span><\/p>\n

protein<\/span><\/td>\n

University of\u00a0\u00a0<\/span><\/p>\n

Queensland\/GSK\/Dynavax<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nNipah, influenza,\u00a0 Ebola, Lassa<\/span><\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Peptide vaccine\u00a0<\/span><\/td>\nFBRI SRC VB VECTOR,\u00a0\u00a0<\/span><\/p>\n

Rospotrebnadzor, Koltsovo<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nEbola<\/span><\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Subunit vaccine\u00a0<\/span><\/td>\nFBRI SRC VB VECTOR,\u00a0\u00a0<\/span><\/p>\n

Rospotrebnadzor, Koltsovo<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

S1 or RBD protein\u00a0<\/span><\/td>\nBaylor College of Medicine\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nSARS<\/span><\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Subunit protein, plant\u00a0 produced<\/span><\/td>\niBio\/CC-Pharming\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Recombinant protein,\u00a0 nanoparticles (based\u00a0 on S-protein and\u00a0\u00a0<\/span><\/p>\n

other epitopes)<\/span><\/td>\n

Saint-Petersburg scientific research\u00a0 institute of vaccines and serums<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

COVID-19 XWG-03 truncated S (spike)\u00a0 proteins<\/span><\/td>\nInnovax\/Xiamen Univ.\/GSK\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nHPV<\/span><\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Adjuvanted\u00a0\u00a0<\/span><\/p>\n

microsphere peptide<\/span><\/td>\n

VIDO-InterVac, University of\u00a0 Saskatchewan<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Synthetic Long\u00a0\u00a0<\/span><\/p>\n

Peptide Vaccine\u00a0\u00a0<\/span><\/p>\n

candidate for S and M\u00a0 proteins<\/span><\/td>\n

OncoGen\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Oral E. coli-based\u00a0 protein expression\u00a0 system of S and N\u00a0 proteins<\/span><\/td>\nMIGAL Galilee Research Institute\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Nanoparticle vaccine\u00a0<\/span><\/td>\nLakePharma, Inc.\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Plant-based subunit (RBD-Fc + Adjuvant)<\/span><\/td>\nBaiya Phytopharm\/ Chula Vaccine\u00a0 Research Center<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

OMV-based vaccine\u00a0<\/span><\/td>\nQuadram Institute Biosciences\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nFlu A, plague<\/span><\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

OMV-based vaccine\u00a0<\/span><\/td>\nBiOMViS Srl\/Univ. of Trento\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

subunit<\/span><\/td>\n

structurally modified\u00a0 spherical particles of\u00a0 the tobacco mosaic\u00a0 virus (TMV)<\/span><\/td>\nLomonosov Moscow State\u00a0\u00a0<\/span><\/p>\n

University<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nrubella,\u00a0\u00a0<\/span><\/p>\n

rotavirus<\/span><\/td>\n<\/tr>\n

Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Spike-based\u00a0<\/span><\/td>\nUniversity of Alberta\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nHepatitis C<\/span><\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Recombinant S1-Fc\u00a0 fusion protein<\/span><\/td>\nAnyGo Technology\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Recombinant protein\u00a0<\/span><\/td>\nYisheng Biopharma\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Recombinant S\u00a0\u00a0<\/span><\/p>\n

protein in IC-BEVS<\/span><\/td>\n

Vabiotech\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Orally delivered, heat\u00a0 stable subunit<\/span><\/td>\nApplied Biotechnology Institute,\u00a0 Inc.<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

S-2P protein + CpG 1018<\/span><\/td>\nMedigen Vaccine Biologics\u00a0\u00a0<\/span><\/p>\n

Corporation\/NIAID\/Dynavax<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Peptides derived from\u00a0 Spike protein<\/span><\/td>\nAxon Neuroscience SE\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Protein Subunit\u00a0<\/span><\/td>\nMOGAM Institute for Biomedical\u00a0 Research, GC Pharma<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

RBD-based\u00a0<\/span><\/td>\nNeovii\/Tel Aviv University\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

RBD-based\u00a0<\/span><\/td>\nKentucky Bioprocessing, Inc\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Outer Membrane\u00a0\u00a0<\/span><\/p>\n

Vesicle (OMV)-\u00a0<\/span><\/p>\n

subunit<\/span><\/td>\n

Intravacc\/Epivax\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Outer Membrane\u00a0\u00a0<\/span><\/p>\n

Vesicle(OMV)-peptide<\/span><\/td>\n

Intravacc\/Epivax\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

DISCLAIMER<\/b>:\u00a0\u00a0<\/b><\/p>\n

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the\u00a0 novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any\u00a0 approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the\u00a0 information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy,\u00a0 completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and\/or non-infringement of any\u00a0 information provided in these landscape documents and\/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility\u00a0 whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement,\u00a0 distribution or use of any product included in any of these landscape documents.\u00a0\u00a0<\/b><\/p>\n

FOLLOWING<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Protein\u00a0\u00a0<\/span><\/p>\n

Subunit<\/span><\/td>\n

Spike-based (epitope\u00a0 screening)<\/span><\/td>\nImmunoPrecise\/LiteVax BV\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Replicating\u00a0 Viral Vector<\/span><\/td>\nYF17D Vector\u00a0<\/span><\/td>\nKU Leuven\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Replicating\u00a0 Viral Vector<\/span><\/td>\nMeasles Vector\u00a0<\/span><\/td>\nCadila Healthcare Limited\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Replicating\u00a0 Viral Vector<\/span><\/td>\nMeasles Vector\u00a0<\/span><\/td>\nInstitute Pasteur\/Themis\/Univ. of\u00a0 Pittsburg Center for Vaccine\u00a0 Research\/Merck<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nWest nile, chik,\u00a0 Ebola, Lassa,\u00a0\u00a0<\/span><\/p>\n

Zika<\/span><\/td>\n<\/tr>\n

Replicating\u00a0 Viral Vector<\/span><\/td>\nMeasles Vector\u00a0<\/span><\/td>\nFBRI SRC VB VECTOR,\u00a0\u00a0<\/span><\/p>\n

Rospotrebnadzor, Koltsovo<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Replicating\u00a0 Viral Vector<\/span><\/td>\nMeasles Virus (S, N\u00a0 targets)<\/span><\/td>\nDZIF \u2013 German Center for Infection\u00a0 Research\/CanVirex AG<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-clinical\u00a0<\/span><\/td>\nZika, H7N9,\u00a0\u00a0<\/span><\/p>\n

CHIKV<\/span><\/td>\n<\/tr>\n

Replicating\u00a0 Viral Vector<\/span><\/td>\nHorsepox vector\u00a0\u00a0<\/span><\/p>\n

expressing S protein<\/span><\/td>\n

Tonix Pharma\/Southern Research\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nSmallpox,\u00a0\u00a0<\/span><\/p>\n

monkeypox<\/span><\/td>\n<\/tr>\n

Replicating\u00a0 Viral Vector<\/span><\/td>\nLive viral vectored\u00a0 vaccine based on\u00a0\u00a0<\/span><\/p>\n

attenuated influenza\u00a0 virus backbone\u00a0<\/span><\/p>\n

(intranasal)<\/span><\/td>\n

BiOCAD and IEM\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nInfluenza<\/span><\/td>\n<\/tr>\n
Replicating\u00a0 Viral Vector<\/span><\/td>\nRecombinant vaccine\u00a0 based on Influenza A\u00a0 virus, for the\u00a0\u00a0<\/span><\/p>\n

prevention of COVID 19 (intranasal)<\/span><\/td>\n

FBRI SRC VB VECTOR,\u00a0\u00a0<\/span><\/p>\n

Rospotrebnadzor, Koltsovo<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nInfluenza<\/span><\/td>\n<\/tr>\n
Replicating\u00a0 Viral Vector<\/span><\/td>\nAttenuated Influenza\u00a0 expressing\u00a0<\/span><\/p>\n

an antigenic portion\u00a0 of the Spike protein<\/span><\/td>\n

Funda\u00e7\u00e3o Oswaldo Cruz and\u00a0<\/span><\/p>\n

Instituto Buntantan<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nInfluenza<\/span><\/td>\n<\/tr>\n
Replicating\u00a0 Viral Vector<\/span><\/td>\nInfluenza vector\u00a0\u00a0<\/span><\/p>\n

expressing RBD<\/span><\/td>\n

University of Hong Kong\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Replicating\u00a0 Viral Vector<\/span><\/td>\nReplication\u00a0<\/span><\/p>\n

competent VSV\u00a0\u00a0<\/span><\/p>\n

chimeric virus\u00a0\u00a0<\/span><\/p>\n

technology (VSV\u0394G)\u00a0 delivering the SARS CoV-2 Spike (S)\u00a0\u00a0<\/span><\/p>\n

glycoprotein.<\/span><\/td>\n

IAVI\/Merck\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nEbola, Marburg,\u00a0 Lassa<\/span><\/td>\n<\/tr>\n
Replicating\u00a0 Viral Vector<\/span><\/td>\nVSV-S\u00a0<\/span><\/td>\nUniversity of Western Ontario\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nHIV, MERS<\/span><\/td>\n<\/tr>\n
Replicating\u00a0 Viral Vector<\/span><\/td>\nVSV vector\u00a0<\/span><\/td>\nFBRI SRC VB VECTOR,\u00a0\u00a0<\/span><\/p>\n

Rospotrebnadzor, Koltsovo<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Replicating\u00a0 Viral Vector<\/span><\/td>\nVSV-S\u00a0<\/span><\/td>\nIsrael Institute for Biological\u00a0 Research\/Weizmann Institute of\u00a0 Science<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Replicating\u00a0 Viral Vector<\/span><\/td>\nM2-deficient single\u00a0 replication (M2SR) influenza vector<\/span><\/td>\nUW\u2013Madison\/FluGen\/Bharat\u00a0 Biotech<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\ninfluenza<\/span><\/td>\n<\/tr>\n
Replicating\u00a0 Viral Vector<\/span><\/td>\nNewcastle disease\u00a0 virus vector (NDV\u00a0<\/span><\/p>\n

SARS-CoV-2\/Spike)<\/span><\/td>\n

Intravacc\/ Wageningen\u00a0\u00a0<\/span><\/p>\n

Bioveterinary Research\/Utrecht\u00a0 Univ.<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Replicating\u00a0 Viral Vector<\/span><\/td>\nAvian paramyxovirus vector (APMV)<\/span><\/td>\nThe Lancaster University, UK\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
RNA\u00a0<\/span><\/td>\nmRNA\u00a0<\/span><\/td>\nSelcuk University\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
RNA\u00a0<\/span><\/td>\nLNP-mRNA\u00a0<\/span><\/td>\nTranslate Bio\/Sanofi Pasteur\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
RNA\u00a0<\/span><\/td>\nLNP-mRNA\u00a0<\/span><\/td>\nCanSino Biologics\/Precision\u00a0\u00a0<\/span><\/p>\n

NanoSystems<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
RNA\u00a0<\/span><\/td>\nLNP-encapsulated\u00a0 mRNA cocktail\u00a0\u00a0<\/span><\/p>\n

encoding VLP<\/span><\/td>\n

Fudan University\/ Shanghai\u00a0\u00a0<\/span><\/p>\n

JiaoTong University\/RNACure\u00a0 Biopharma<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
RNA\u00a0<\/span><\/td>\nLNP-encapsulated\u00a0 mRNA encoding RBD<\/span><\/td>\nFudan University\/ Shanghai\u00a0\u00a0<\/span><\/p>\n

JiaoTong University\/RNACure\u00a0 Biopharma<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
RNA\u00a0<\/span><\/td>\nReplicating Defective\u00a0 SARS-CoV-2 derived\u00a0 RNAs<\/span><\/td>\nCentro Nacional Biotecnolog\u00eda\u00a0 (CNB-CSIC), Spain<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
RNA\u00a0<\/span><\/td>\nLNP-encapsulated\u00a0 mRNA<\/span><\/td>\nUniversity of Tokyo\/ Daiichi-Sankyo\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nMERS<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

DISCLAIMER<\/b>:\u00a0\u00a0<\/b><\/p>\n

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the\u00a0 novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any\u00a0 approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the\u00a0 information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy,\u00a0 completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and\/or non-infringement of any\u00a0 information provided in these landscape documents and\/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility\u00a0 whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement,\u00a0 distribution or use of any product included in any of these landscape documents.\u00a0\u00a0<\/b><\/p>\n

FOLLOWING<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
RNA\u00a0<\/span><\/td>\nLiposome\u00a0<\/span><\/p>\n

encapsulated mRNA<\/span><\/td>\n

BIOCAD\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
RNA\u00a0<\/span><\/td>\nSeveral mRNA\u00a0<\/span><\/p>\n

candidates<\/span><\/td>\n

RNAimmune, Inc.\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
RNA\u00a0<\/span><\/td>\nmRNA\u00a0<\/span><\/td>\nFBRI SRC VB VECTOR,\u00a0\u00a0<\/span><\/p>\n

Rospotrebnadzor, Koltsovo<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
RNA\u00a0<\/span><\/td>\nmRNA\u00a0<\/span><\/td>\nChina CDC\/Tongji\u00a0\u00a0<\/span><\/p>\n

University\/Stermina<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
RNA\u00a0<\/span><\/td>\nmRNA\u00a0<\/span><\/td>\nArcturus\/Duke-NUS\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nmultiple\u00a0\u00a0<\/span><\/p>\n

candidates<\/span><\/td>\n<\/tr>\n

RNA\u00a0<\/span><\/td>\nLNP-mRNA\u00a0<\/span><\/td>\nChula Vaccine Research\u00a0\u00a0<\/span><\/p>\n

Center\/University of Pennsylvania<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
RNA\u00a0<\/span><\/td>\nmRNA in an intranasal\u00a0 delivery system<\/span><\/td>\neTheRNA\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
RNA\u00a0<\/span><\/td>\nmRNA\u00a0<\/span><\/td>\nGreenlight Biosciences\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
RNA\u00a0<\/span><\/td>\nmRNA\u00a0<\/span><\/td>\nIDIBAPS-Hospital Clinic, Spain\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
VLP\u00a0<\/span><\/td>\nVLP\u00a0<\/span><\/td>\nMiddle East Technical University\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
VLP\u00a0<\/span><\/td>\nEnveloped Virus-Like\u00a0 Particle (eVLP)<\/span><\/td>\nVBI Vaccines Inc.\u00a0<\/span><\/td>\nSARS-CoV-2, SARS-CoV, &\u00a0 MERS-CoV<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nCMV, GBM, Zika<\/span><\/td>\n<\/tr>\n
VLP\u00a0<\/span><\/td>\nS protein integrated\u00a0 in HIV VLPs<\/span><\/td>\nIrsiCaixa AIDS Research\/IRTA CReSA\/Barcelona Supercomputing\u00a0 Centre\/Grifols<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
VLP\u00a0<\/span><\/td>\nVLP + Adjuvant\u00a0<\/span><\/td>\nMahidol University\/ The\u00a0\u00a0<\/span><\/p>\n

Government Pharmaceutical\u00a0 Organization (GPO)\/Siriraj Hospital<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
VLP\u00a0<\/span><\/td>\nVirus-like particles,\u00a0 lentivirus and\u00a0\u00a0<\/span><\/p>\n

baculovirus vehicles<\/span><\/td>\n

Navarrabiomed, Oncoimmunology\u00a0 group<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
VLP\u00a0<\/span><\/td>\nVirus-like particle,\u00a0 based on RBD\u00a0\u00a0<\/span><\/p>\n

displayed on virus-like\u00a0 particles<\/span><\/td>\n

Saiba GmbH\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
VLP\u00a0<\/span><\/td>\nADDomerTM\u00a0<\/span><\/p>\n

multiepitope display<\/span><\/td>\n

Imophoron Ltd and Bristol\u00a0\u00a0<\/span><\/p>\n

University\u2019s Max Planck Centre<\/span><\/td>\n

SARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
VLP\u00a0<\/span><\/td>\nUnknown\u00a0<\/span><\/td>\nDoherty Institute\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
VLP\u00a0<\/span><\/td>\nVLP\u00a0<\/span><\/td>\nOSIVAX\u00a0<\/span><\/td>\nSARS-CoV1 SARS-CoV2<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
VLP\u00a0<\/span><\/td>\neVLP\u00a0<\/span><\/td>\nARTES Biotechnology\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical\u00a0<\/span><\/td>\nmalaria<\/span><\/td>\n<\/tr>\n
VLP\u00a0<\/span><\/td>\nVLPs peptides\/whole\u00a0 virus<\/span><\/td>\nUniv. of Sao Paulo\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n
Unknown\u00a0<\/span><\/td>\nUnknown\u00a0<\/span><\/td>\nTulane University\u00a0<\/span><\/td>\nSARS-CoV2\u00a0<\/span><\/td>\nPre-Clinical<\/span><\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

DISCLAIMER<\/b>:\u00a0\u00a0<\/b><\/p>\n

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the\u00a0 novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any\u00a0 approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the\u00a0 information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy,\u00a0 completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and\/or non-infringement of any\u00a0 information provided in these landscape documents and\/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility\u00a0 whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement,\u00a0 distribution or use of any product included in any of these landscape documents.\u00a0\u00a0<\/b>
\n<\/b><\/p>\n

The time required to develop a new vaccine <\/span>since the discovery of a new virus until the Marketing Authorization\u00a0 <\/span>At least 13 years<\/b><\/p>\n

– <\/span>Identification of the virus <\/b>responsible for the epidemic<\/span>: <\/span>1 year\u00a0<\/b><\/p>\n

– <\/span>Development of a vaccine: <\/b>8 years<\/b>, <\/b>according to Dr Fr\u00e9d\u00e9ric Tangy in Paris-Match from 14-20 May 2020 <\/span>– <\/span>Preclinical studies <\/b>: <\/span>analytical<\/span>, <\/span>galenical<\/span>, and <\/span>toxicological in animals<\/span>: <\/span>1 year <\/b>– <\/span>Study in humans:\u00a0<\/b><\/p>\n

– Phase I: <\/b>in <\/span>healthy volunteers <\/b>after favorable opinion of Protection Committee,<\/span> and <\/span>Free<\/b> an <\/span>I<\/b>nformed Consent<\/b> of healthy voluntary subjects : <\/span>6 <\/b>months <\/b>to <\/span>1 year\u00a0\u00a0<\/b><\/p>\n

– <\/span>Phase II<\/b>: in <\/span>100 <\/b>to <\/span>1000 subjects <\/b>a<\/span>fter favorable opinion of Protection Committee<\/span> and <\/span>Free<\/b> and <\/span>Informed Consent<\/b> of all subjects: <\/span>6 months <\/b>to <\/span>1 year\u00a0\u00a0<\/b><\/p>\n

– Phase III: <\/b>in <\/span>10 000 <\/b>to <\/span>100 000 subjects or more <\/b>a<\/span>fter favorable opinion of Protection<\/span>\u00a0 <\/span>Committee<\/span> and <\/span>Free<\/b> and <\/span>Informed Consent<\/b> of all subjects<\/span>: <\/b>6 months <\/b>to <\/span>1 year\u00a0<\/b><\/p>\n

During development you cannot go from one study phase to the next,\u00a0 without having the results of the previous phase\u00a0<\/span><\/p>\n

Protocols for clinical studies of 2 Covid-19 vaccines <\/b>ChAdOx1 nCoV-19 <\/b>and <\/b>mRNA-1273 <\/b>vaccines\u00a0<\/b><\/p>\n

(Written by the N.I.H.)\u00a0\u00a0<\/span><\/p>\n

1- <\/b>Protocol of the University of Oxford \/ Astra Zeneca Phase I study with the ChAdOx1 nCoV-19 vaccine\u00a0<\/b><\/p>\n

– <\/span>Sponsor <\/b>of the study: Research Services, University Offices Wellington Square, Oxford, 1200, United Kingdom\u00a0<\/span><\/p>\n

– <\/span>Country <\/b>of the study: <\/span>South Africa\u00a0<\/b><\/p>\n

– Summary of the study: <\/b>A Phase I\/II, double-blinded, placebo-controlled, individually randomized trial to assess safety, immunogenicity and efficacy of the candidate Coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults aged 18-65 years living with and without HIV in South Africa. The vaccine or placebo will be administered via an intramuscular injection into the deltoid muscle of the non dominant arm. A total of 2000 participants will be enrolled into the trial; 1950 HIV-uninfected and 50 people living with HIV. There will be 4 trial groups, group 1 (n=50; intensive safety & immunogenicity cohort, HIV negative), group 2a (n=250; safety, intense immunogenicity & efficacy), group 2b (n=1650; safety, immunogenicity & vaccine efficacy) and group 3 (n=50, intensive safety & immunogenicity cohort, HIV positive). Participants will be followed up for 12 months after enrollment.\u00a0<\/span><\/p>\n

– Ethics Approval: <\/b>approval given on May, 21, 2020, by University of the Witwatersrand Human Research Ethics Committee Medical, 31 Princess of Wales Terrace, Parktown, Johannesburg, 2193, South Africa\u00a0<\/span><\/p>\n

– 2000 healthy <\/b>volunteer <\/span>subjects <\/b>aged <\/span>between 18 <\/b>and <\/span>65 years\u00a0<\/b><\/p>\n

– <\/span>Starting <\/b>of the study: <\/span>June 24, 2020\u00a0<\/b><\/p>\n

– <\/span>End <\/b>of the study: <\/span>December 31, 2021<\/b>
\n<\/b><\/p>\n

Protocols for clinical studies of 2 Covid-19 vaccines\u00a0<\/b><\/p>\n

ChAdOx1 nCoV-19 <\/b>and <\/b>mRNA-1273 <\/b>vaccines\u00a0<\/b><\/p>\n

(Written b y th e N .I.H.)\u00a0\u00a0<\/span><\/p>\n

Following<\/span>\u00a0\u00a0<\/span><\/p>\n

2 – <\/b>Protocol of the University of Oxford \/ Astra Zeneca Phase II \/ III study with\u00a0 <\/b>the <\/b>ChAdOx1 nCoV-19 <\/b>vaccine<\/b><\/p>\n

– Title of the study: <\/b>A phase 2\/3 study to determine the efficacy, safety and immunogenicity of t he candidate\u00a0 Coronavirus Disease (COVID-19) vaccine ChAdOx1 n CoV-19\u00a0<\/span><\/p>\n

– Country <\/b>of the study: <\/span>United-Kingdom\u00a0<\/b><\/p>\n

– Sponsor of the study: <\/b>ResearchServices, U niversity Offices Wellington Squa re, <\/span>Oxford,1200, U nited Kingdom\u00a0<\/span><\/p>\n

– Summary of the study: <\/b>To e valuate the e fficacy o f the candidate ChAdOx1 nCoV-19 in adults aged 18 and\u00a0 over.To a ssess t he safety of t he C hAdOx1 n CoV-19 vaccine candidate in adults a nd c hildren.To a ssess the\u00a0 safety, tolerability and reactogenicity profile of the ChAdOx1 nCoV-19 candidate\u00a0<\/span><\/p>\n

– Favorable opinion <\/b>of the Competent Authority: April 5 , 2020\u00a0<\/span><\/p>\n

– Favorable opinion <\/b>of the Ethics Committee<\/span>: <\/b>April 8 , 2020\u00a0<\/span><\/p>\n

– 12 390 healthy volunteer subjects <\/b>divided into 4 age g roups: <\/span>60 under <\/b>the age of <\/span>18. 60 children <\/b>aged\u00a0 between <\/span>2 <\/b>and <\/span>11 <\/b>years old. <\/span>12,030 adults <\/b>aged be tween <\/span>18 <\/b>and <\/span>64 <\/b>years o ld. <\/span>240 subjects <\/b>aged <\/span>over 65\u00a0<\/b><\/p>\n

– Starting <\/b>of the st udy: <\/span>May, 2020\u00a0<\/b><\/p>\n

– End <\/b>of the study: <\/span>May, 2021\u00a0<\/b>
\n<\/b><\/p>\n

Protocols for clinical studies of 2 Covid-19 vaccines\u00a0 <\/b>ChAdOx1 nCoV-19 <\/b>and mRNA-1273 vaccines\u00a0\u00a0<\/b><\/p>\n

(Written by the N.I.H.)\u00a0\u00a0<\/span><\/p>\n

Following<\/span>\u00a0<\/span><\/p>\n

3- <\/b>University of Oxford \/ Astra Zeneca Phase III study protocol <\/b>with <\/span>ChAdOx1 nCoV-19 vaccine\u00a0<\/b><\/p>\n

– <\/span>Title of the study<\/b>: A phase III randomized controlled trial to determine safety, efficacy, and immunogenicity of the non-replicating <\/span>ChAdOx1 nCoV-19 vaccine\u00a0<\/b><\/p>\n

– <\/span>Country <\/b>of the study: <\/span>Brazil\u00a0<\/b><\/p>\n

– <\/span>Ethics approval<\/b>: Approval pending:\u00a0<\/span><\/p>\n

    \n
  1. The National Commission for Research Ethics (Comiss\u00e3o Nacional de \u00c9tica em Pesquisa, (CONEP) – Brazil <\/span>2. <\/span>Oxford Tropical Research Ethics Committee (OxTREC) – UK\u00a0<\/span><\/li>\n<\/ol>\n

    – <\/span>2000 healthy volunteer subjects aged between 18 and 55 years\u00a0<\/b><\/p>\n

    – <\/span>Starting <\/b>of the study: <\/span>May 1, 2020\u00a0<\/b><\/p>\n

    – <\/span>End <\/b>of the study: <\/span>July 31, 2021<\/b><\/p>\n

    Protocols for clinical studies of 2 Covid-19 vaccines\u00a0\u00a0<\/b><\/p>\n

    ChAdOx1 nCoV-19 <\/b>and <\/b>mRNA-1273 <\/b>vaccines\u00a0\u00a0<\/b><\/p>\n

    (Written by the N.I.H.)\u00a0\u00a0<\/span><\/p>\n

    Following\u00a0\u00a0<\/span><\/p>\n

    4- <\/b>Protocol for Phase I study of Moderna with their new vaccine mARN-1273\u00a0<\/b><\/p>\n

    – <\/span>Title of the study<\/b>: Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV2 Infection COVID-19. This is a <\/span>phase I<\/b>, open-label, <\/span>dose-ranging clinical trial <\/b>in males and nemales, starting at 18 years of age\u00a0<\/span><\/p>\n

    – <\/span>Sponsor of the study<\/b>: National Institute of Allergy and Infectious Diseases (NIAID)\u00a0<\/span><\/p>\n

    – <\/span>Country <\/b>of the study: <\/span>United States of America <\/b>(Georgia, Maryland, Washington)\u00a0<\/span><\/p>\n

    – Summary <\/b>of the study: This is a <\/span>phase I, open-label, dose-ranging clinical trial <\/b>in males and non-pregnant females, starting 18 years of age, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of mRNA-1273 manufactured by ModernaTX, Inc. mRNA-1273 is a novel lipid\u00a0 nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike (S) protein of\u00a0 SARS-CoV-2. Enrollment will occur at up to 3 domestic clinical research sites. One hundred and fifty-five subjects will be\u00a0 enrolled into one of thirteen cohorts (10 micrograms [mcg], 25 mcg, 50 mcg, 100 mcg, and 250 mcg). Subjects will receive an\u00a0 intramuscular (IM) injection (0.5 milliliters [mL]) of mRNA-1273 on Days 1 and 29 in the deltoid muscle and will be\u00a0 followed through 12 months post second vaccination (Day 394). Follow-up visits will occur 1, 2, and 4 weeks post each\u00a0 vaccination (Days 8, 15, 29, 36, 43, and 57), as well as 3, 6, and 12 months post second vaccination (Days 119, 209, and\u00a0 394).\u00a0<\/span><\/p>\n

    – <\/span>Ethics approval<\/b>: ???\u00a0<\/span><\/p>\n

    – <\/span>155 healthy volunteer <\/b>subjectsaged <\/span>between 18 <\/b>and <\/span>99 <\/b>years\u00a0<\/span><\/p>\n

    – <\/span>Starting <\/b>of the study: <\/span>March 16, 2020\u00a0<\/b><\/p>\n

    – <\/span>End <\/b>of the study: <\/span>November 22, 2021<\/b>
    \n<\/b><\/p>\n

    Protocols for clinical studies of 2 Covid-19 vaccines\u00a0 <\/b>ChAdOx1 nCoV-19 <\/b>and <\/b>mRNA-1273 <\/b>vaccines\u00a0\u00a0<\/b><\/p>\n

    (Written by the N.I.H.)\u00a0\u00a0<\/span><\/p>\n

    Following\u00a0\u00a0<\/span><\/p>\n

    5- <\/b>Protocol for Phase II study of Moderna with their new vaccine mARN-1273\u00a0<\/b><\/p>\n

    – <\/b>Title of the study: <\/b>A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation\u00a0 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine\u00a0 in Adults Aged 18 Years and Older\u00a0<\/span><\/p>\n

    – Sponsor <\/b>of the study: <\/span>Moderna TX, Inc.\u00a0<\/b><\/p>\n

    – Collaborators: <\/b>Biomedical Advanced Research and Development Authority<\/span>\u00a0<\/span><\/p>\n

    – Country <\/b>of the study: <\/span>United States of America .\u00a0<\/b><\/p>\n

    – Locations: <\/b>Georgia, Kansas, Missouri, Nebraska, North Carolina, South Dakota, Texas, Utah. <\/span>– Ethics approval: <\/b>Studies a U.S. FDA-regulated Drug Product ???\u00a0<\/span><\/p>\n

    – 600 healthy <\/b>volunteer <\/span>subjects aged <\/b>between <\/span>18 <\/b>and <\/span>55+\u00a0<\/b><\/p>\n

    – Starting <\/b>of the study: <\/span>May 20, 2020\u00a0<\/b><\/p>\n

    – End <\/b>of the study: <\/span>August, 2021<\/b>
    \n<\/b><\/p>\n

    COVID-19 Vaccine: <\/b>ChAdOx1 nCoV-19\u00a0<\/b><\/p>\n

    According to information provided by the NIH and WHO, 160 vaccines against\u00a0 Covid-19 are under development. But, after reviewing Phase 1, 2 and 3 clinical\u00a0 studies, the protocols of which were all written by the NIH, and their\u00a0 advancement, <\/span>we came to the following c onclusion<\/span>:\u00a0\u00a0<\/span><\/p>\n

    The only vaccine that has been developed\u00a0\u00a0<\/b><\/p>\n

    and already manufactured for several months\u00a0\u00a0<\/b><\/p>\n

    is the ChAdOx1 nCoV-19\u00a0\u00a0<\/b><\/p>\n

    All other 159 vaccines are “decoys”\u00a0<\/b><\/p>\n

    ChAdOx1 nCoV-19 <\/span>i<\/span>s the r esult of a co llaboration between the Institut\u00a0 Pasteur (Sanofi) and th e Jenner Institute (AstraZeneca).\u00a0<\/span><\/p>\n

    In <\/span>ChAdOx1 nCoV-19 <\/span>, the genome of Covid-19 coronavirus is carried\u00a0 by the Chimpanzee adenovirus <\/span>ChAdOx1<\/span>, which serve s as a viral vector<\/span><\/p>\n

    COVID-19 Vaccine: <\/b>ChAdOx1 n-CoV-19\u00a0<\/b><\/p>\n

    In the only v accine de veloped and put into production, <\/span>t he genome of the Covid-19\u00a0 <\/b>coronavirus <\/span>is carried by the <\/b>Chimpanzee adenovirus ChAdOx1<\/b>,\u00a0 <\/span>which <\/span>serves as a viral vector<\/b><\/p>\n

    ChAdOx1 nCoV-19<\/b>: <\/span>C ovid-19 <\/b>coronavirus carried\u00a0\u00a0<\/span><\/p>\n

    by the vector viru<\/span>s ChAdOx1 <\/b>Nanoparticles <\/b>described in <\/span>Micr osoftPaten t\u00a0 PCT\/ U S201 9\/ 038084 <\/span>,which <\/span>will control you t hanks t o 5 G\u00a0<\/span><\/p>\n

    Disinfectant : <\/b>s: <\/b>either <\/span>T himerosal\u00a0<\/b><\/p>\n

    or <\/span>Formaldehyde\u00a0<\/b><\/p>\n

    and antibiotics\u00a0<\/span><\/p>\n

    To read the full article see <\/b>DOCUMENT <\/b>5<\/span> (Download PDF)\u00a0<\/span><\/p>\n

    To read the original interview see <\/b>Document 6<\/b>\u00a0<\/b><\/p>\n

    Extract from the interview with Dr Tangy in PARIS-MATCH from May 14-20, 2020\u00a0<\/span><\/p>\n

    Among the 400 emails received each day by Professor Etienne Simon-Lori\u00e8re, responsible for the\u00a0 functional genomic unit for infectious diseases, there is always one sent by an unknown person\u00a0 who found his contact on the Internet: where are they? vaccine research? On this point, Fr\u00e9d\u00e9ric\u00a0 Tangy, head of the vaccine innovation laboratory, does not want to leave any doubt. With a sigh,\u00a0 he said: <\/span>“There will be no miracle vaccine in November or December. At best, it will be in 2021.\u201d <\/span>\u00a0He\u00a0 even\u00a0 plagues\u00a0 against\u00a0 figures\u00a0 which, according\u00a0 to\u00a0 him, sow\u00a0 confusion. <\/span>\u00a0Thus, those\u00a0 of\u00a0 the <\/span>\u00a0<\/span>London School of Hygiene & Tropical Medicine which has just listed 120 vaccines in development <\/span>\u00a0<\/span>in the world\u2026. \u201c<\/span>It can be misleading. <\/span>There are maybe only eight that will result!<\/span> And of those,\u00a0 tested in China, Britain, Germany or the United States, few are expected to progress from phase\u00a0 1\u00a0 to\u00a0 phase\u00a0 2\u00a0 of\u00a0 human\u00a0 clinical\u00a0 trials.\u00a0 Industrialists\u00a0 know\u00a0 this\u00a0 very\u00a0 well:\u00a0 most\u00a0 are\u00a0 just\u00a0 new\u00a0 strategies, having not yet shown any clinical proof. I call them “mouse vaccines”. Vaccine science,\u00a0 the\u00a0 real\u00a0 one,\u00a0 the\u00a0 one\u00a0 that works,\u00a0 doesn’t move\u00a0 that way. In\u00a0 half an\u00a0 hour,\u00a0 he will\u00a0 transmit a\u00a0 videoconference,\u00a0 recorded\u00a0 the day before,\u00a0 to an audience of\u00a0 scientists\u00a0 from\u00a0 the Academy of\u00a0 Sciences. <\/span>It deals specifically with the steps required to develop a vaccine. <\/span>“Look at my diagrams: <\/b>\u00a0<\/b>a vaccine is at least eight years of research! <\/b>The AIDS vaccine has been on it for thirty-five years,\u00a0 and it’s still very difficult.\u00a0\u00a0<\/span><\/p>\n

    According to Dr Fr\u00e9d\u00e9ric Tangy, the father of Covid-19, <\/b>it takes at least 8 years <\/b>\u00a0<\/b>to develop a vaccine<\/b> (interview in Paris-Match from May 16 to 20, 2020)<\/b><\/p>\n

    Interview with Bill Gates Paris-Match April 16-22, 2020\u00a0\u00a0<\/span><\/p>\n

    Bill Gates-doctor of the world\u00a0\u00a0<\/b><\/p>\n

    To read the original version of the interview, see <\/b>DOCUMENT 7<\/b>\u00a0<\/b><\/p>\n

    To read an excerpt translated into English, see <\/b>DOCUMENT 8<\/b>\u00a0<\/b><\/p>\n

    In 2015, Bill Gates sounded the alarm <\/b>at a press conference\u00a0 that will go viral: nearly 30 million people have watched it to date.\u00a0 <\/span>It describes the catastrophic scenario that the entire planet\u00a0 has experienced since the start of the Covid-19 epidemic\u00a0<\/b><\/p>\n

    It’s easy to predict a pandemic when you start it<\/b>
    \n<\/b><\/p>\n

    To read the full article see <\/b>DOCUMENT <\/b>9<\/span><\/p>\n

    To read the full article<\/b>s see <\/span>DOCUMENT<\/b>S 10 et 11<\/span><\/p>\n

    TREATMENT OF COVID-19 VIRAL INFECTION\u00a0 WITH HYDROXYCHLOROQUINE\u00a0\u00a0<\/span><\/p>\n

    Justification for the use of:\u00a0<\/span><\/p>\n

    – Hydroxychloroquine\u00a0<\/span><\/p>\n

    – Hydroxychloroquine and Azithromycin (or an antibiotic from\u00a0 the family of macrolides or tetracyclines):\u00a0\u00a0<\/span><\/p>\n

    T<\/b>o read the full article see DOCUMENT 20 (USB Key)<\/b><\/p>\n

    T<\/b>o read the full article see DOCUMENT 22 (USB Key<\/b>)<\/b><\/p>\n

    1-Unit\u00e9 de Parasitologie. D\u00e9partement d\u2019infectiologie de terrain, Institut de Recherche Biom\u00e9dicale des Arm\u00e9es, Marseille, France. 2-Unit\u00e9 de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, UM 63,\u00a0 CNRS\u00a0 7278, IRD\u00a0 198, Inserm\u00a0 1095,\u00a0 Aix Marseille Universit\u00e9, Marseille,\u00a0 France.\u00a0 3-F\u00e9d\u00e9ration\u00a0 des\u00a0 Laboratoires, H\u00f4pital\u00a0 d\u2019Instruction\u00a0 des\u00a0 Arm\u00e9es\u00a0 Sainte\u00a0 Anne, Toulon,\u00a0 France.\u00a0 4-Equipe\u00a0 R\u00e9sidente\u00a0 de\u00a0 Recherche en Infectiologie Tropicale, Institut de Recherche Biom\u00e9dicale des Arm\u00e9es, Marseille, France. 5-Centre National de R\u00e9f\u00e9rence du Paludisme, Marseille, France. 6-Unit\u00e9 de Parasitologie et d\u2019Entomologie, D\u00e9partement des\u00a0<\/span><\/p>\n

    Maladies Infectieuses, , Institut de Recherche Biom\u00e9dicale des Arm\u00e9es, Br\u00e9tigny sur Orge, France.\u00a0<\/span><\/p>\n

    Why Agn\u00e8s BUZYN and Olivier VERAN\u00a0 have banned the prescription\u00a0\u00a0<\/span><\/p>\n

    of Hydroxychloroquine\u00a0\u00a0<\/span><\/p>\n

    to Covid-19 infected people ?\u00a0\u00a0<\/span><\/p>\n

    Agn\u00e8s BUZYN and Yves LEVY know that DNA fragments from the\u00a0 germ of Malaria are inserted into the genome of Covid-19<\/span>(see <\/span>DOCUMENT 2<\/span>)\u00a0\u00a0<\/span><\/p>\n

    Under these conditions, administration of hydroxychloroquine\u00a0 destroys the genome of Covid-19 and stops the infection.\u00a0<\/span><\/p>\n

    WARNING\u00a0<\/b><\/p>\n

    – <\/span>Covid-19 helped spark a false pandemic, a<\/b>nd <\/span>spread fear across the world<\/b>, <\/span>to make us accept the Covid-19 vaccine.\u00a0<\/b><\/p>\n

    – <\/span>By seeking to vaccinate the entire world population, the sponsors of this vaccine, <\/span>Bill Gates and his\u00a0 allies<\/b>, want <\/span>to enslave <\/b>and <\/span>control us<\/b>, pursuing two objectives:\u00a0<\/span><\/p>\n

    – <\/span>Control the entire world population <\/b>after having vaccinated it, <\/span>thanks to the deployment of 5G<\/b>; <\/span>– <\/span>Limit the world’s population<\/b>.\u00a0<\/span><\/p>\n

    \u00a0This vaccine is very dangerous because it will cause, in vaccinated people, deleterious\u00a0 <\/span>immunodeficiency, due, in particular, to the HIV sequences of its genome.\u00a0\u00a0<\/span><\/p>\n

    MEN WORLDWIDE MUST REFUSE COVID-19 VACCINE THAT\u00a0 BILL GATES AND ITS ALLIES WANT TO IMPOSE ON US\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-76303","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"http:\/\/stateofthenation.co\/index.php?rest_route=\/wp\/v2\/posts\/76303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/stateofthenation.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/stateofthenation.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/stateofthenation.co\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/stateofthenation.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76303"}],"version-history":[{"count":0,"href":"http:\/\/stateofthenation.co\/index.php?rest_route=\/wp\/v2\/posts\/76303\/revisions"}],"wp:attachment":[{"href":"http:\/\/stateofthenation.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/stateofthenation.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76303"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/stateofthenation.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}